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THE GENETIC BASIS OF DIABETIC RETINOPATHY 
 
Bashira Abdullah Charles, Ph.D. 
University of Pittsburgh, 2008 
 
Diabetic retinopathy (DR) is a microvascular complication of diabetes and proliferative 
diabetic retinopathy (PDR) is the most vision threatening form of DR and the leading cause of 
blindness in individuals aged 20-74 years.  Genetic endowment is thought to play a role in 
development of DR.   The adenosine A2 receptor (ADORA2A) is associated with decreased tissue 
impairment caused by inflammation, hypoxia, and oxidative stress, while vascular endothelial 
growth factor (VEGF) is associated with hypertension, vascular permeability, and 
neoangiogenesis, and is elevated in those with DR.  The aim of this study was to determine if the 
ADORA2A or the VEGF genes are associated with prevalent baseline PDR (PBPDR) or 
prospective incident PDR (PIPDR) in participants of the Epidemiology of Diabetes 
Complications (EDC) prospective study of childhood onset type 1 diabetes.  Two tagging single 
nucleotide polymorphisms (tSNPs) of the ADORA2A gene (rs2236624 and rs4822489) and 4 
SNPs of the VEGF gene (rs2146323, rs833069, rs699947, rs10434) were genotyped and 
assessed for association with prevalence and incidence of PDR, while controlling for traditional 
covariates. 
Univariate analysis of ADORA2A rs2236624 was associated with PBPDR [OR=1.68; 
(95%CI=1.11-2.54); p=0.03] and PIPDR [HR=0.17; (95%CI=0.04-0.69); p=0.01].  These 
associations were sustained in the multivariate analysis with rs2236624-CT being significantly 
associated with PBPDR [OR=2.17; (95%CI=1.24-3.81); p=0.03].  In the Cox analysis 
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rs2236624-CT [HR= 1.54; (95%CI=1.08-2.18); p=0.02] and rs2236624-TT [HR=0.10; 
(95%CI=0.01-0.72); p= 0.02] were significantly associated with PIPDR.  Analysis of the 
rs4822489 tSNP found an association between the GT genotype and PIPDR in the univariate 
analysis [HR=1.53 ;( 95%CI: =1.12-2.09); p=0.008], and in the multivariate analyses [HR=1.57 
;( 95%CI: =1.13-2.17); p=0.0067] after controlling for covariates.  To determine if there was 
increased risk associated with the 4822489 genotypes and PBPDR participants were stratified 
into late onset (PDR ≥25 years T1d duration), early onset (PDR<25 years T1D duration), and 
protected (No PDR during follow-up) groups.  Those with the GT genotype had a significantly 
increased association [OR=1.93; (95%CI: =1.11-3.35); p=0.03] with early onset PDR compared 
to the protected group.  The association between the GT genotype of the rs4822489 tSNP was 
only marginally significant [OR=1.73 ;( 95%CI: =0.89-3.36); p=0.12] in the multivariate 
analyses after controlling for covariates.  Furthermore univariately, the GG genotype of VEGF 
rs10434 was marginally [OR=1.3; (95%CI=0.75-2.28); p=0.14) associated with PBPDR but, 
multivariately significantly [OR=2.47; (95%CI=1.15-5.3); p=0054] associated with baseline 
PBPDR.  Hypertension status [OR=3.93 (95%CI=1.98-7.8); p =<0.0001] low density lipoprotein 
[OR=1.01 ;( 95%CI=1.004-1.02); p=0.0050] and duration [OR=1.21 (95%CI=1.12-1.3); 
p=<0.0001] were also significantly associated with PBPDR.   None of the VEGF SNPs were 
associated with PIPDR.  Additional analysis showed a significant (p=0.045) direct univariate 
association between the AG genotype of rs10434 and hypertension. 
In the EDC population heterozygosity for the rs2236624 tSNP of the ADORA2A gene is 
associated with susceptibility to PDR while homozygosity for the (T) allele of rs2236624 tSNP is 
associated with protection form development of incident PDR.  While homozygosity of the 
  v
VEGF rs10434 tSNP is associated with baseline prevalent PDR and heterozygosity for the 
rs10434 tSNP is associated with baseline prevalent hypertension. 
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1.0  INTRODUCTION 
1.1 DIABETES AND ITS COMPLICATIONS 
Numerous advances have been made in understanding the etiology of human illness 
through mapping and analysis of the human genome.  Researchers have discovered the genetic 
basis for various disease processes and have developed treatments based upon this information.  
Diabetes is a metabolic disorder, which results in hyperglycemia, and before the advent of 
medical therapy, death.   Due to advances in medical therapy, diabetic patients live longer; 
however, they often develop complications related to diabetes, such as, retinopathy, nephropathy, 
neuropathy, and cardiovascular disease.  These complications are the source of most of the 
illnesses and deaths of diabetic patients.  As documented by the American Diabetes Association, 
greater than $170 billion of the healthcare dollars spent were attributed to medical and other 
costs related to diabetes in 2007.   Fifty-eight billion dollars of those expenses were used to treat 
diabetes complications and an additional $58 billion were used to cover costs related to 
absenteeism, work loss, unremitting disability and premature death.  Additionally, it has been 
estimated that the prevalence of diabetes will be more than twofold greater in 2050 than it was in 
2005 (American Diabetes Association 2008).   Given the increase in the incidence and therefore 
the prevalence of diabetes, the cost of its care in the years to come will be much greater.   
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Determining the genetic basis of susceptibility to diabetes complications and/or genes 
associated with early onset of diabetes complications would offer nurses and other health care 
providers information that would facilitate not only early detection of at risk patients and 
implementation of appropriate therapies, but would also give healthcare providers the knowledge 
to educate their patients about their risks and modifications that may prevent or delay the onset 
of complications of their disease.   After 15 to 30 years of type 1 diabetes (T1D) the majority of 
these patients will have some form of retinopathy (Stefansson, Bek et al. 2000; Sheetz and King 
2002).  Much of the literature has addressed genes associated with development or susceptibility 
to DR; however, few to date have addressed genes associated with why some patients differ in 
their length of DR free diabetes or why some patients with T1D progresses more rapidly to 
proliferative diabetic retinopathy, the more severe form of the vision corrupting disease.   
1.2 DIABETIC RETINOPATHY 
Diabetic retinopathy (DR) is a microvascular complication of diabetes characterized by 
micro-aneurysms, neovascularization with poorly formed weak vessels, vascular rupture, and 
bleeding in the retina.  DR is the leading cause of new cases of blindness in individuals between 
the second and the seventh decades of life, and accounts for approximately 24,000 new cases of 
blindness annually (Centers for Disease Control and Prevention 2005; American Diabetes 
Association 2007).  Approximately 20 million individuals in the United States have diabetes and 
most of these individuals will experience some form of DR during the course of their lives; 
however, those with type 1 diabetes (T1D) will experience a higher incidence of DR and will 
experience more vision threatening forms of DR with 90% developing DR once they have had 
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diabetes for 15 years and 60% developing proliferative DR once they have had diabetes for 20 
years (Koulu, Movafagh et al. 2004). 
1.3 PURPOSE 
The purpose of this study was to investigate genes potentially associated with length of 
time from diagnosis of type 1 diabetes (T1D) to the development of proliferative diabetic 
retinopathy (PDR) as well as attainment of PDR.   This project focused on a population of 
patients diagnosed with T1D for a minimum of 25 years, who had been followed every 2 years 
for clinical assessment including development of complications, and investigated a possible 
genetic contribution to the development of PDR.   
1.4 SPECIFIC AIMS 
Specific Aim 1: Determine if a specific allele, specific genotype or haplotype generated 
for each candidate gene is associated with length of time to diagnosis PDR in individuals with 
T1D. 
Specific Aim 2:  Determine if a specific allele, specific genotype and/or haplotype 
generated for each candidate gene is associated with attainment of PDR.   
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1.5 CONCEPTUALIZATION 
The conceptual framework for this project is demonstrated in the figure below. 
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Figure 1: Conceptual Framework 
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2.0  BACKGROUND AND SIGNIFICANCE 
This section includes information on diabetic retinopathy, information to support a 
genetic-based investigation into susceptibility to PDR, and information about angiogenesis and 
vasculogenesis and how it relates to PDR.   
2.1 PREVALENCE AND PATHOPHYSIOLOGY OF DIABETIC RETINOPATHY 
It is estimated that 2.4 million Americans have T1D (American Diabetes Association 
2007) representing approximately one in every 400-600 children and adolescents in the United 
States or up to 10% of all confirmed cases of diabetes (Centers for Disease Control and 
Prevention 2005; American Diabetes Association 2007).  Diabetic retinopathy is a microvascular 
complication of diabetes; therefore it makes sense to study genes involved with angiogenesis and 
vasculogenesis as plausible contributors to development of susceptibility to, or protection from 
the development of DR.  Greater than 12,000, and possibly as high as 24,000 persons with 
diabetes, are diagnosed with retinopathy each year (American Diabetes Association 2007; 
National Eye Institute 2008).  Diabetic retinopathy causes visual disturbances and is the most 
prevalent cause of new onset blindness in individuals 20-74 years of age (Centers for Disease 
Control and Prevention 2005; American Diabetes Association 2007).  The pathogenesis of DR 
has four stages (National Eye Institute 2008).  Prior to the first stage of DR and in association 
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with hyperglycemia, pericyte (contractile cell) cell death begins (Sheetz and King 2002).  In stage 
one or Mild Nonproliferative Retinopathy the weakening of the vessels following the death of 
pericytes causes microaneurysms to develop in the microvasculature of the retina (National Eye 
Institute 2008).  The second stage of DR or Moderate Nonproliferative Retinopathy is associated 
with impairment in the blood supply of vessels of the retina caused by clot formation (Petrovic, 
Hawlina et al. 2003; National Eye Institute 2008).  The third stage of DR or Severe 
Nonproliferative Retinopathy is marked by increased impaired blood flow through the vessels 
supplying the retina and vascular neogenesis (formation of new vessels).  The fourth and most 
severe stage of DR is Proliferative Retinopathy, which is marked by increasing vascular 
neogenesis near the vitreous humor.  These new vessels are weak and malformed (National Eye 
Institute 2008).  It has been estimated that after 15 years with diabetes 75-97.5% of individuals 
develop some form of DR (Klein, Klein et al. 1984; Sheetz and King 2002).   DR may worsen 
over time; however, not everyone progresses to proliferative DR.  In the cases where it does 
progress these vascular changes may cause blindness by vitreous hemorrhage or by retinal 
detachment caused by fibrosis (Frank 2004; National Eye Institute 2008).    
2.2 ANGIOGENESIS AND VASCULOGENESIS 
A complex series of metabolic reactions utilizing different biologic pathways occur in the 
presence of hyperglycemia.  Metabolic pathways that are activated during hyperglycemia 
influence the cellular environment and expose the cells to many toxic substances.  Although this 
is a process that occurs in all individuals experiencing hyperglycemia, the non diabetic individual 
will respond by producing enough insulin to return blood sugar levels to a euglucemic state, thus 
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decreasing the non diabetic’s exposure to hyperglycemia and the physiologic responses that 
include the production of substances toxic to the cells.  In contrast to the response of the 
individual without diabetes, individuals with diabetes have blood sugar levels that are elevated 
more frequently and for more extended periods of time.  Some claim that these glycemic 
elevations are responsible for changes in the extracellular matrix resulting in capillary basement 
membrane thickening (Akbari and LoGerfo 1999).  Furthermore, when the cells are exposed to 
hypoxia or toxic substances the cells may become injured, dysfunctional and die.  The toxic 
substances that the cells are exposed to include sorbitol (increasing osmotic pressure), hydrogen 
peroxide, lactate, toxic levels of glucose, reactive oxygen species, and advanced glycation end 
products. This exposure may lead to an increase in inflammation.  Furthermore hypoxia and 
vascular cell injury may result in pericyte cell death, and with progression, formation and rupture 
of aneurisms (Chowdhury, Kumar et al. 1992; Sheetz and King 2002; Boehm, Lang et al. 2003; 
Kumaramanickavel, Sripriya et al. 2003; Whikehart 2003).  Capillary rupture results in plasma 
lipids and proteins being deposited over time resulting in the formation of solid exudates (Sheetz 
and King 2002). The rupture of these vessels triggers increased hypoxia and vascular impairment 
stimulating a pathophysiologic response which attempts to repair the injured vascular system of 
the eye. Unfortunately the new vessels are weak and ill formed.   As mentioned above, in 
individuals without diabetes this feedback mechanism is not activated as frequently or for 
extended periods of time, therefore this  pathologic growth of new vessels is not activated in the 
individual without diabetes (Boehm, Lang et al. 2003). 
     The abnormal vascular growth and the physiologic and pathophysiologic mechanisms 
mentioned above have lead to the postulation that one’s genetic endowment from a myriad of 
genes, each having multiple possible variants with their own pleiotropic effect may influence 
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one’s susceptibility to complications of diabetes, particularly retinopathy, stage of DR attained 
and length of PDR free diabetes.  Because the primary debilitating clinical manifestation of 
diabetic retinopathy is abnormal vascular growth it makes sense to explore the relationship 
between multiple genes in the vasculogenic and angiogenic pathway for an association between 
their variants and the development of proliferative diabetic retinopathy.  It is also plausible that 
various combinations of these variants create a biologic environment that produces individual 
susceptibility to or protection from the development of diabetic retinopathy, non-proliferative 
diabetic retinopathy and proliferative retinopathy, as well as influencing the length of PDR free 
diabetes. 
     The mechanisms involved with vasculogenesis and angiogenesis are not completely 
understood.  At one time angiogenesis was identified as being the development of newly formed 
blood vessels arising from previously formed blood vessels, while vasculogenesis was identified 
as being the formation of blood vessels from single predecessor cells called angioblasts during 
embryogenesis.  Investigators now believe that the lines between these two processes are not so 
clearly drawn (Auerbach and Auerbach 2001).  
     The process of angiogenesis and vasculogenesis is required for the development and 
sustenance of healthy and pathologic tissues (Hackett, Ozaki et al. 2000).   The vasculogenic and 
angiogenic processes involved in the development of the vascular system within the retina have 
been described (Hughes, Yang et al. 2000). The vasculature of the retina is composed of a very 
thin, small complex of capillaries sandwiched between an exterior and interior layer of vessels.  
When the retina is in the presence of uncontrolled hyperglycemia, toxic substances, such as 
sorbitol and advanced glycation end products (AGEs), are produced.  Investigators postulate that 
these substances cause pericyte cell death, resulting in the development of microaneurysm 
  8
formation.  Ex-vivo experiments have illustrated that pericyte cell death is followed by the rapid 
growth of endothelial cells, a process which has lead investigators to postulate that the death of 
pericytes leads to the initiation of proliferative and nonproliferative diabetic retinopathy 
(Hammes, Lin et al. 2002; Wauiter and Schmidt 2004).  When aneurysms form and rupture the 
areas that the ruptured vessel/s feed are deprived of oxygen, resulting in a hypoxic state.  Hackett 
et al have demonstrated that neovascularization develops in response to the ischemic retina 
(Campochiaro 2000; Hackett, Ozaki et al. 2000).  While the exact mechanisms involved in the 
activation of neoangiogenesis are not clearly understood, it is associated with the expression of 
cytokines, extracellular matrix proteins, vasoactive peptide, integrin receptors, and angiopoeitins 
(Knott, Robertson et al. 1999; Jones 2001; Pepper, Mandriota et al. 2001; Rodriguez and Brooks 
2001; Walsh and Fan 2001). 
2.3 RATIONALE FOR INVESTIGATING THE GENETIC BASIS OF 
DIABETIC RETINOPATHY 
Animal and human models provide empirical evidence that supports the possibility of a 
genetic susceptibility in some individuals toward developing DR.  This complication of diabetes 
tends to cluster in racial groups and families of individuals with known diabetes.  Family 
Evidence:  Using a United States population with diabetes drawn from the third National Health 
and Nutrition Examination Survey investigators found that among individuals with type 2 
diabetes, Mexican Americans were more likely to develop all stages of DR than were Non-
Hispanic Blacks, and Non-Hispanic Blacks were more likely to develop all stages of DR than 
were Non-Hispanic Whites, while Non-Hispanic Blacks without diabetes were less likely to 
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develop any form of retinopathy than Mexican Americans or Non-Hispanic Whites (Harris, Klein 
et al. 1998).  Other investigators have reported conflicting results with regard to the prevalence of 
DR among Hispanic verses Non-Hispanic Whites and suggest that the prevalence between the 
two groups is actually similar (Tudor, Hamman et al. 1998).  A more recent study using data from 
the 2001 Behavioral Risk Factor Surveillance System (BRFSS) found that Whites had a lower 
prevalence of DR than Blacks, Hispanics, or Native Americans, while Asians had a higher 
prevalence of DR than all four previously mentioned groups and Pacific Islanders had the highest 
prevalence of DR among all of the groups (McNeely and Boyko 2005).  Other investigators have 
estimated that among individuals with T1D prevalence of any DR is 75% as opposed to 82% in 
Black and Whites respectively.  While prevalence of PDR is 30% as opposed to 32% in Black 
and White individuals with T1D, respectively (Roy, Klein et al. 2004).  The NIH and estimates 
that among all individuals with known diabetes 59.2% of Hispanics, 36.08 % of Whites, 31.19% 
of Blacks and 44.25% of all others have prevalent DR (National Eye Institute 2002).  Family 
Evidence: The Diabetes Control and Complications Trial (DCCT) found that some patients with 
poor glycemic control never developed DR, while other patients who maintained good glycemic 
control did develop DR.  This discordance between the expected physiologic response based on 
glycemic control and the actual development of DR in some individuals suggests that there must 
be some other basis for this phenomenon other than glycemic control and length of time with 
diabetes (Diabetes Control & Complications Trial 1993).   Subsequently, a family clustering 
study of DR was conducted using the same population.  This study noted a positive relationship 
between DR severity and family clustering.  In other words severity of DR appeared to have a 
similar pattern within the same family clusters (Diabetes Control and Complications Trial 1997).  
This phenomena, supports the probability of a genetic based etiology for developing DR.    
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Additionally a family clustering study of South Indian families with at least 2 siblings with 
diabetes was conducted between 1991 and 1997.  A total of 355 siblings participated in the study.  
DR was diagnosed in 21.4% of these siblings and there was a 35.3% concordance in their diabetic 
siblings while in the 78.6% of siblings without DR  only11.2% in their diabetic siblings had DR 
(Rema, Saravanan et al. 2002) 
In a Mexican American population, after controlling for duration of diabetes and glycemic 
control, investigators found that more vision threatening forms of DR tended to cluster in families 
after they combined individuals with moderate non-proliferative DR and individuals with PDR 
into one group (Hallman, Boerwinlle et al. 2007).  These finding were supported by a study of 
767 families (n=2368) with diabetes.  These investigators found that severity of DR tended to 
aggregate within families (Arar, Freedman et al. 2008).  In all these findings support a rationale 
for exploring a genetic basis for DR or severity of DR attained. 
Genes within the angiogenesis and vasculogenesis pathways mentioned above will be 
investigated for an association between the development of diabetic retinopathy and variants of 
identified genes.  Variants to be investigated in this project will be tagging SNPs with a minor 
allele frequency of 20% or greater and are illustrated in the table noted below: 
 
Table 1: Variants for this project based on their involvement in angiogenesis and vasculogenesis. 
GENE FUNCTION        HAPMAP   TAGGED  SNPS REFERENCES 
Vascular 
Endothelial Growth
Factor 
(VEGF) 
 
Associated with vascular permeability, 
controls/induces neoangiogenesis and is 
elevated in DR.  Upregulation induced 
by advanced glycation end 
products. 
(2) 
rs10434 
rs833069 
rs2146323 
(Duh and Aiello 1999) 
(Caldwell, Bartoli et al. 2003) 
(Nakagawa, Chen et al. 2000) 
(Lu, Kuroki et al. 1998 ) 
(Perrin, Konopatskaya et al. 2005)
(HapMap 2006) 
Adenosine A2 
Receptor 
(ADORA2A) 
Modulates activity of vascular cells 
including protection from stress such 
as ischemia and limits the inflammatory 
response and cell injury in animal models.
(2) 
rs4822489 
rs2236624 
(HapMap 2006) 
(McKusick 2006) 
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 2.4 VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) 
CHROMOSOME 6P12 
In 1948 Michaelson postulated that there was an unknown factor that accounted for the 
growth of new vessels in the retina (Michaelson 1948); however, vascular endothelial growth 
factor was not isolated and identified as being a necessary component of normal and pathologic 
angiogenesis (vascular growth) via initiation of vascular endothelial cell proliferation, migration, 
and tube formation until 1991 (Favard, Moukadiri et al. 1991; McKusick 2006; Penn, Madan et 
al. 2008).  Retinal hypoxia, is a component of the pathological response to the hyperglycemic 
state and VEGF is up-regulated in the presence of hypoxia (Campochiaro 2000; Hackett, Ozaki et 
al. 2000; Perrin, Konopatskaya et al. 2005).  Oxidative stress and inflammation are also  part of 
the pathologic response to  hyperglycemia and  these processes also result in the up-regulation of 
VEGF (Favard, Moukadiri et al. 1991), which is a primary trigger for the neoangiogenesis and 
the weak leaky vessels characterized by DR (Perrin, Konopatskaya et al. 2005).  Furthermore, 
VEGF has been well defined in both animal and human models as contributing to the 
development of DR.  Starting n the 1990s animal and human studies identified an association 
between VEGF and the ocular fluid of rats, primates and humans with DR (Aiello, Avery et al. 
1994; Miller, Adamis et al. 1994; Nakagawa, Chen et al. 2000).  Subsequently genetic association 
studies were conducted in Japanese, East Indian and Caucasian populations, all of which reported 
significant associations between VEGF variants and the prevalence of some form of DR.  These 
associations have been confirmed in individuals with T1D and T2D.  In 2002 investigators 
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reported an association between DR and the 5’-untranslated region (C-634) of the VEGF gene in 
a population of 268 Japanese patients with T2D (Awata, Inoue et al. 2002).  Later, investigators 
in England reported an association between the VEGF-460C polymorphism and development of 
PDR in a Caucasian population of individuals with T1D and T2D (Ray, Mishra et al. 2004).  In a 
population of 210 T2D patients of east Indian ancestry investigators found that the C(-7)T, the 
T(-1498)C, and the C(-634)G, polymorphisms of the VEGF gene were significantly associated 
with DR (Suganthalakshmi, Anand et al. 2006).  Interestingly, Nakamura and colleagues found an 
association between the -2578AApolymorphism but not the C(-634)G, polymorphism of the 
VEGF gene and prevalence of DR  (Nakamura, Iwasaki et al. 2008).  Investigators of the DCCT 
provided evidence that three SNPs (rs3025007, rs3025020 and rs3025035) of the VEGF gene 
were associated with severe retinopathy in a univariate model; while eight SNPs (rs699947, 
rs833070, rs2146323, rs3035007, rs3025010, rs3025020, rs3025021, rs3025028) were associated 
with severe retinopathy in the multivariate analysis (Al-Kateb, Mirea et al. 2007).  Finally, 
investigators in England provided evidence that two SNPs in the promoter region (rs13207351-
160 CC genotype and the -152 AA genotype, and rs1570360-116 AA genotype) were 
significantly associated with PDR in a mixed T1D and T2D population (Churchill, Carter et al. 
2008). 
2.5 ADENOSINE 2A RECEPTOR (ADORA2A) 
    It is postulated that oxidative stress (OS) caused by long term exposure to 
hyperglycemia may be responsible for some of the tissue damage associated with complications 
of diabetes.  OS is elevated in the retina of individuals with diabetes and may contribute to the 
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development of DR (Pan, Zhang et al. 2008).  In the presence of OS hydrogen peroxide is formed 
in the cytosol  rendering the vascular endothelial cells more permeable (Hecquet, Ahmmed et al. 
2008).  In contrast adenosine, derived from ATP metabolism, is a powerful physiologic mediator, 
thought to modulate cellular damage and the resulting tissue injury caused by biologic stressors.  
This modulation by adenosine is directed by the adenosine receptors (AR), with the Adenosine 
A1 receptor having a proinflammatory response to tissue injury while the  adenosine A2 receptor 
(ADORA2) restricts inflammation and guards tissues from further damage (Salmon, Brogle et al. 
1993; McKusick 2006).  Investigators in Italy provided evidence that ARs have variability in 
function and the subsequent responses to ischemia found in the rat brain (Trincavelli, Melani et 
al. 2008).  Other animal studies have provided evidence that ADORA2A protects the heart from 
ischemic reperfusion injury by reducing the generation of ROS, by limiting mitochondrial 
damage and by guarding against apoptosis (Xu, Mueller et al. 2005; Xu, Park et al. 2005).  
ARORA2A also contributes to activation of physiologic pathways that protect kidney cells from 
injury due to ischemia and reperfusion (Yonehana and Gemba 1999).  Many of ADORA2A’s 
affects in humans have not yet been elucidated.  The role ADORA2A plays in ameliorating the 
effects of biologic stressors in animals coupled with the fact that adenosine’s effects are 
modulated by the ARs makes ADORA2A gene a plausible candidate gene for exploring 
susceptibility or protection from the development of DR.  It may also affect the severity of DR 
attained.  The ADORA2A receptor gene is located on chromosome 22q11.2.  This gene has been 
further characterized in the manuscript “ADORA2A is Associated with Proliferative Diabetic 
Retinopathy in Type 1 Diabetes”.   
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3.0   PRELIMINARY STUDIES   
Preliminary analysis of each SNP was conducted upon receipt of the assay from ABI to 
assess quality of the assay.  Additionally after each SNP was genotyped additional analysis were 
conducted to assess whether or not the SNP genotypes were in Hardy-Weinberg equilibrium.  
Please see Table 2 for the ADORA2A tSNPS and Table 3 for the VEGF SNPs. 
 
Table 2: ADORA2A Allele Frequencies and Genotype Frequencies 
ADORA2A 
Rs2236624 Rs4822489 
Allele Frequencies Allele Frequencies 
C 0.79 G 0.61 
T 0.21 T 0.39 
Genotype Frequencies Genotype Frequencies 
CC 308 GG 195 
CT 154 GT 212 
TT 24 TT 84 
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Table 3: VEGF Allele Frequencies and Genotype Frequencies 
VEGF 
RS699947 RS833069 
Allele Frequencies Allele Frequencies 
A 0.45 C 0.35 
C 0.55 T 0.65 
Genotype Frequencies Genotype Frequencies 
AA 101 CC 66 
AC 233 CT 212 
AA 148 TT 212 
RS2146323 RS10434 
Allele Frequencies Allele Frequencies 
A 0.32 A 0.46 
C 0.68 G 0.54 
Genotype Frequencies Genotype Frequencies 
AA 52 AA 102 
AC 210 AG 241 
CC 227 GG 141 
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4.0  RESEARCH DESIGN AND METHODS 
Additional Research Design and Methods details can be found within the manuscripts 
contained within this document. 
4.1 RESEARCH DESIGN 
The design of specific aim 1 uses a nested association approach focusing on the genes 
which may be associated with the time of PDR free diabetes.  Survival analysis methods will be 
used to assess the participants in biennial increments from time of diagnosis of diabetes until 
onset of PDR. 
The design of specific aim 2 uses a case control association study approach focusing on 
the genetic susceptibility to or protection from proliferative diabetic retinopathy.  The cases will 
be comprised of individuals who have been affected with Type 1 diabetes (T1D) for a minimum 
of 25 years who have documented proliferative diabetic retinopathy.  The controls will be 
comprised of individuals who have been affected with T1D for a minimum of 25 years who have 
NOT developed proliferative diabetic retinopathy.  Please see Table 4 for counts and frequencies 
related to DR status of EDC study participants. 
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Table 4: Development of diabetic retinopathy in the EDC study 
IDDM Duration at time Number with DR Percent of participants 
5-9 44 2% 
10-14 104 7% 
15-19 147 22% 
20-24 113 38% 
25-29 102 77% 
30+ 68 68% 
30+ 79***Never developed  
4.2 SAMPLE 
The population for this study consists of 496 (75.4%) of the 658 participants of the 
Pittsburgh Epidemiology of Diabetes Complications (PEDC) Study for whom banked DNA was 
available.  These participants offer a unique opportunity to investigate the genetic contribution to 
the development of PDR, because there is extensive clinical data available for them as well as 
banked DNA.  The clinical data were derived from clinical assessments which were conducted at 
baseline then approximately every 2 years over a 20-year period.  The assessments included, 
presence of complications, including a retinal exam during which fundus photos were taken; 
blood pressure; duration of diabetes complications; body mass index; glycosylated hemoglobin; 
total cholesterol; low density lipoprotein; high density lipoprotein; triglycerides; ever smoker 
status; HbA1C; homocysteine; antibodies to oxidized LDL; water and lipid soluble antioxidants 
including uric acid; α and γ tocopherol; thiols and cystatin-C; apoB, cellular adhesion molecules 
such as ICAM-1 and VCAM-1; P and E selectin; IL-1, IL-6; IL-8m, TNF α ; TGFβ; CTGF; 
complete lipid profile; PAI-1; fibrinogen; adiponectin; a CBC; and C reactive protein.  Females 
represent 49.5% of the study population and the racial representation is similar to that of the 
Allegheny County T1D registry which consists of  4.6% African American, 95.4% Caucasian 
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and no representation from other ethnicities, while the EDC participants consists of 2% African-
American and 98% Caucasian.   
Table 5: Retinal assessment categories 
Category 1 Category 2 Category 3 Category 4 
No Retinopathy Early 
Background Retinopathy 
Advanced Retinopathy Proliferative 
Retinopathy 
Grade 10 in Both Eyes Grade 20 or 30 in Either Eye Grade 40 or 50 in Either 
Eye 
Grade 60 or > 
in Either Eye 
 
4.3 RECRUITMENT 
The recruitment pool consisted of members of the Children’s Hospital of Pittsburgh 
diabetes registry which treated 70% of all T1D patients in Allegheny County. Potential 
participants received a letter inviting them to have a physical examination and to complete 
several questionnaires.  There were 979 eligible participants, 658 (67.2%) of whom participated 
in the entire EDC evaluation process (Kostraba, Klein et al. 1991; Costacou, Chang et al. 2006).  
The current study, “Genetic Basis of Diabetic Retinopathy” (GBDR) consists of 496 (75.4%) 
EDC participants.   The remaining 24.6% of the participants were excluded due to lack of genetic 
material.   
Inclusion criteria for the PEDC and GBDR studies: 
• Childhood-onset of type 1 diabetes  
• Live within 100 miles or 2 ½ hour drive to Children’s Hospital of Pittsburgh 
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• Banked DNA 
Exclusion criteria for the EDC and GBDR studies: 
• Adult onset diabetes mellitus of any type 
• Lack of availability of banked DNA due to missed visit 
This study was approved by the Institutional Review Board at the University of 
Pittsburgh and written informed consent was obtained from participants prior to baseline data 
collection.   
Measures/Instruments: DNA samples:  DNA was extracted from leukocytes and banked 
using a unique numerical identification system.  These DNA samples are stored in 1X TE buffer, 
and are of adequate concentration to allow for the collection of the genotypes required for this 
study and were made available for the purpose of this study through Dr. Trevor J. Orchard and 
Dr. Robert E. Ferrell.   
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4.4 RESEARCH SETTING 
 Genetic Laboratory:  All genotyping for the GBDR study was conducted in Dr. 
Yvette P. Conley’s Laboratory located at 3500 Victoria Street on the fourth floor of the 
University of Pittsburgh school of Nursing.  It is comprised of 4 areas: 
1. A pre-PCR room 
2. A post-PCR room 
3. A culture room 
4. A cold storage room 
5. A room temperature storage room 
These rooms are housed in a 3200 square foot area.  The lab provides an ABI 377 
automated sequencer/genotyper with accessory computer equipment and software for data 
analysis, the WAVE® Nucleic Acid Fragment Analysis System from Transgenomic which 
carries out dHPLC, a Turner Designs Luminometer, myriad horizontal and vertical 
electrophoresis units and power packs, a computerized camera and gel documentation software, 
centrifuges, a spectrophotometer, -80 degree freezers, five 96 well thermocyclers and an ABI 
7000 TaqMan® real time PCR and allele discrimination assays. 
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4.5 PROCEDURES  
Genotype Data Collection Methods:  
Bioinformatics for SNP selection:   Tagging single nucleotide polymorphisms (tSNPs) 
for each gene were selected using the HapMap database (NCBI build 35) (hapmap.org) 
(HapMap, 2008) using criteria of a minor allele frequency of 20% or greater and an r2 cut off of 
.80.  An ABI Prism® 7000 Sequence Detection System was used to conduct allelic discrimination 
using TaqMan® assays.  This is a highly automated, high throughput genotyping method for 
SNPs.  Primers flank each polymorphism and PCR is conducted using subject DNA.  The main 
difference between TaqMan® PCR and general PCR is the use of a probe that is labeled with a 
reporter and a quencher dye that recognizes a specific allele of a SNP.  Each allele of a SNP has 
its own probe with its own reporter dye.  If the subject’s DNA is homozygous for one allele of 
the SNP, only the probe for that allele will hybridize and only the reporter dye for that allele will 
be liberated and measured by the ABI Prism® 7000 Sequence Detection System.  A heterozygote 
will have both probes hybridize and both reporter dyes measured.  Using this method, each SNP 
can be genotyped accurately and quickly.   Assay-on-demand kits or made to order kits were 
purchased from ABI for each of the selected SNPs.   These kits supplied the primers, probes, and 
reagents for the genotyping of each of these SNPs.  In addition the PCR conditions for each SNP 
had been established by ABI and were supplied with the purchase of the assays.  The Taqman 
Genotyping conditions are noted below.  When the results yielded poor separation using the 
normal protocol, the extended protocol was used and generally resulted in improved separation 
and allelic discrimination. 
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TaqMan Conditions- Normal Protocol: 
• Step 1: 50ºC for 2 minutes UNG enzyme activation 
• Step 2: 95ºC for 10 minutes AmpliTaq Gold  
• Step 3: 95ºC for 15 seconds to denature DNA 
• Step 4: 60ºC for 1 minute for annealing  and strand extension 
• Step 5: Repeat from Step three 30 times 
 
TaqMan Conditions- Extended Protocol:  
• Step1: 50ºC for 2 minutes UNG enzyme activation 
• Step 2: 95ºC for 10 minutes AmpliTaq Gold  
• Step:3 95ºC for 15 seconds to denature DNA 
• Step 4: 58ºC for 1 minute and 30 seconds for annealing  and strand extension 
• Step 5: Repeat from step three 50 times 
• Table 6: TaqMan Genotyping Conditions and Protocol for ADORA2A: 
 
Table 6: TaqMan Genotyping Conditions and Protocol for ADORA2A 
Gene 
ADORA2A 
Assay on 
Demand (20X) 
Concentration 
Made To 
Order (40X) 
Concentration 
Genomiphied 
DNA and H2O 
5:100(ul) 
Universal 
PCR Mix 
(ul) 
Assay 
(ul) 
TaqMan 
Conditions 
Rs2236624  Yes 5.7ul 6.25 0.3125 Extended 
Rs4822489 Yes  5.7ul 6.25 0.625 Extended 
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Table 7: TaqMan Genotyping Conditions and Protocol for VEGF 
Gene 
VEGF 
Assay on 
Demand (20X) 
Concentration 
Made To 
Order (40X) 
Concentration 
Genomiphied 
DNA and H2O 
5:100(ul) 
Universal 
PCR Mix 
(ul) 
Assay 
(ul) 
TaqMan 
Conditions 
Rs699947  Yes 5.7 6.25 0.3125 Normal 
Rs2146323  Yes 5.7 6.25 0.3125 Normal 
Rs8333069  Yes 5.7 6.25 0.3125 Normal 
Rs10434  Yes 5.7 6.25 0.2125 Extended 
4.6 DATA MANAGEMENT 
SNP genotypes were placed in Excel spreadsheets using the unique identifiers assigned to 
the specimen prior to receipt of the specimen.  The genotype data and the existing EDC data 
were merged by a unique case identification number using SAS 9.1.3 statistical software (SAS 
Institute Inc 2000-2004).  The merged data was maintained in a separate database on a password 
protected computer. 
4.7 DATA ANALYSIS  
Statistical analyses were also conducted using SAS version 9.1.3 statistical software.  
Prior to the conduct of primary analyses to address the specified research aims, a detailed 
preliminary analysis was conducted, and included a descriptive analysis of collected data, a 
summarization of data and the use of inferential and graphic exploratory data analytic techniques 
to identify any data abnormalities.  Categorical variables, such as PDR status, gender, race, 
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hypertension status, ever smoker status, and genetic endowment with genotypes of a particular 
tagging SNP, were described using frequency tables (with frequency counts and percentages) 
and contingency.  Continuous variables such as duration of diabetes and age, were assessed using 
frequency distributions, histograms, box plots, normal probability plots, and/or stem and leaf 
plots. The shape of the distribution of continuous variables was described in terms of degree of 
normality, skewness kurtosis.  The mean and standard deviation of continuous variables were 
used to describe the variable’s central tendency (i.e. location) and dispersion.  The presence of 
univariate and multivariate outliers was assessed using Box plots, histograms, and normal 
probability, detrended normal probability, and bivariate scatter plots.  Multicollinearity was 
assessed using variance inflation factor, tolerance indices, and collinearity diagnostics (i.e., 
condition indices and variance decomposition proportions).  Variance inflation factor values 
greater than 10, tolerance values less than 0.10 and a conditioning indices more than 30 for a 
given predictor variable paired with at least 2 variance decomposition proportions greater than 
.50 were deemed to be indicative of multicollinearity.  and/or collinearity values greater than or 
equal to 25  were  judged to be indicative of multicolinearity.  Data transformations were applied 
as necessary (i.e., squared, quadratic and cubed).   
Survival analysis and ordinal logistic regression methods were used in the primary 
analysis of the data.  Prior to the use of these methods, key assumptions specific to the method 
were evaluated (e.g., linearity of the logit, proportional odds assumptions, proportional hazards 
assumption).  Survival analysis methods were used to assess Specific Aim 1.  Initially a crude 
analysis of each SNP was investigated for its association with length of time to diagnosis of PDR 
using Kaplan-Meier curves.  Univariate Cox proportional hazards regression was used to assess 
the predictive association between the SNP genotypes and incident PDR.  When controlling for 
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covariates, multivariate Cox proportional hazards regression methods were employed.  The 
covariates were identified in the preliminary analysis using stepwise Cox proportional hazards 
regression methods.  Covariates found to be significant (in the preliminary analysis were 
included in the multivariate analysis along with SNP’s genotypes to investigate their joint 
association with length of time to development of PDR.   
  For Specific Aim 2 proportional odds logistic regression analysis was used to investigate 
the association between prevalent PDR attainment and the SNPs listed Table 1.  Subjects were 
categorized by PDR status.  Initially, each SNP was be analyzed for its crude (unadjusted) 
association with PDR attainment using exact chi square analysis to assess independence and to 
accommodate possible sparseness of cells.  The genotypes of the SNPs were assessed using 
backward selection bivariate logistic regression and a .10 level of significance for covariate 
removal.  Covariates were selected using univariate logistic regression.  Lastly, the SNPs were 
be analyzed for PDR attainment taking the covariates into consideration using stepwise logistic 
regression analysis and a significance level of .05 for covariate entry and .10 for variable 
removal.  Model assessment (i.e., residual analysis, identification of influential observations0 
was performed for all proportional odds and proportional hazards models estimated.. 
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5.0  PUBLICATIONS 
This section consists of two abstracts submitted for publication.  The first abstract reports 
the findings of the ADORA2A gene and  gene and its association with PDR in the EDC derived 
GBDR population, while the second abstract reports the results of the investigation of the VEGF 
gene and its association with PDR in the EDC derived GBDR population. 
5.1 ABSTRACT #1: ADORA2A  
Purpose:  The ADORA2A receptor ameliorates many of the deleterious physiologic 
effects associated with tissue injury and biologic stressors.  It may also ameliorate some of the 
biologic stressors experienced by individuals with diabetes.  Thus, we investigated cross-
sectionally and prospectively association between the ADORA2A gene and proliferative diabetic 
retinopathy (PDR) in a sample of patients with type 1 diabetes (T1D). 
Methods:  Study participants were from the Pittsburgh Epidemiology of Diabetes 
Complications (EDC) prospective study of childhood onset (<17 years) T1D, (mean age 28 
years, mean diabetes duration 19 years at enrollment).  Participants underwent stereoscopic 
images of the retinal fundus at baseline (1986-1988) then biennially, over 20 years.  PDR was 
defined as grade ≥ 60 in one eye or < 60 but with panretinal photocoagulation scars consistent 
with laser therapy, according to the modified Airlie House system.  Two haplotype blocks for the 
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ADORA2A gene and two tagging single nucleotide polymorphisms (tSNPs) were selected using 
HAPMAP (rs2236624 and rs4822489) 
Results:  Univariate and multivariate logistic regression analysis of the rs2236624 tSNP 
revealed an association between the CT genotype and prevalent PDR at baseline, OR=1.68; 
(95%CI=1.11-2.54); p=0.03 and OR=2.17; (95%CI=1.24-3.81); p=0.03, respectively.   
Univariate and multivariate Cox proportional hazards regression analysis of rs2236624 revealed 
an association between the TT genotype and decreased incidence of PDR hazard ratio (HR) = 
.169; (95%CI=0.042); p=0.01 and HR = 0.101 (95%CI = 0.014-0.724), respectively.  While the 
CT genotype was marginally associated with increased incidence of PDR in the univariate 
analysis HR=1.34; (95%CI:=0.96-1.87);p=0.09 and significantly associated with incidence of 
PDR in the multivariate analysis HR=1.54;(95%CI:=1.08-2.18);p=0.02. 
Conclusions: Homozygosity for the TT genotype appears to be protective against PDR 
development, while heterozygosity increases PDR incidence. 
5.2 ABSTRACT #2: VEGF 
Purpose:  The VEGF gene, particularly the 5 prime untranslated region has been 
implicated in diabetic retinopathy (DR), a microvascular complication of diabetes characterized 
by erratic vessel formation and visual impairment brought on by hypoxia and the damaging 
byproducts of glucose metabolism in individuals with diabetes.   The purpose of this study was to 
investigate the VEGF gene within the context of proliferative diabetic retinopathy (PDR), the 
most severe form of DR, in a sample of patients with type 1 diabetes (T1D). 
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Methods:  Participants of this study were drawn from the Pittsburgh Epidemiology of 
Diabetes Complications (EDC) prospective study of childhood onset T1D.  The mean age was 28 
years and the mean diabetes duration was 19 years for EDC participants at baseline.  Participants 
had stereoscopic images of the retinal fundus at baseline (1986-1988) then biennially for 20 
years.  PDR was defined as grade ≥ 60 in one eye but < 60 but with panretinal photocoagulation 
scars consistent with laser therapy, according to the modified Arlie House system.  Three 
haplotype blocks for the VEGF gene and 3 tagging single nucleotide polymorphisms (tSNPs) 
were selected using HAPMAP (rs2146326, rs833069 and rs10434).  We decided to investigate 
two additional SNPs based on their significance in a similar population (rs3025021 and 
rs699947). 
Results:  Only rs10434 (GG) was marginally associated with PDR at baseline OR=1.29, 
(95% CI=0.75-2.26) and significantly associated with PDR in the multivariate analysis OR=2.47 
(95% CI=1.15-5.29).  Additional analysis revealed an association between rs10434 (AG) and 
hypertension [OR=2.13(95%CI=1.16-3.89); p=0.05].  These finding warrants further 
investigation as hypertension is a confounder, significantly associated with the rs10434 AG 
genotype and significantly associated with PDR, while, and the GG genotype of rs10434 is 
associated with PDR. 
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6.0  RESEARCH PARTICIPANT RISK AND PROTECTION 
6.1 HUMAN PARTICIPANTS 
The Genetic Basis of Diabetic Retinopathy study consists of 496 (75.4%) of the 658 
participants of the EDC study for whom genetic material was available.   The age of the 
participants at entry time of entry into the EDC study ranged from 8-48 years.  The mean age 
was 28 years.  Criteria for study participation required that all participants 1) were diagnosed 
with T1D prior to age 17 years, 2) lived 200 miles or within 2 and a half hour drive from 
Children’s Hospital of Pittsburgh and 3) had no adult onset of any type of diabetes.   
The specimens used in the study were collected by the Pittsburgh Epidemiology of 
Diabetes Complications (EDC) study.  The specimens were coded and de-identified.   The PI for 
the GBDR study had no connection to the EDC study data collection or the specimen collection 
sites.  She also had no access to any personal information or identifiers that could be used to link 
personal identifiers to the study participants. 
6.2 VULNERABLE POPULATIONS 
Inclusion of Children:  This study is interested in the susceptibility to complications of 
diabetes, which typically does not occur until the subject has had the disease for some time.  
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Therefore the participants, diagnosed with diabetes as children, agreed to participate in the study 
however, informed consent was granted by their adult parents when the participant was recruited 
into the EDC study.  Additionally all participants underwent a consent process for each EDC 
visit therefore as that became adults former childhood participants were able to grant their own 
informed consent for participation in the EDC study. 
Inclusion of Women and Minorities:  The data set for the GBDR study was an existing 
data set which consisted of the participants of the Pittsburgh Epidemiology of Diabetes 
Complications study (EDC); hence minority recruitment, age and gender of the study 
participants were pre-established.  There were a total of 658 participants available for the GBDR 
study through the EDC study.  The study population for the EDC consists of 325 (49.5%) female 
and 333 (50.5%) male participants, and the racial representation parallels that of the Allegheny 
County T1D registry being 4.4% African American and 95.4% Caucasian.  None of the 
participants are of Hispanic, Asian, American Indian, Alaskan, Hawaiian or other descent.  The 
percentage of African Americans in the EDC study population reflects the lower incidence of 
T1D in African-Americans as well as reflecting the population in the Pittsburgh area.  Subjects 
enrolled in the EDC study were recruited from the Pittsburgh area within Allegheny County.  
The population found in this region is 84.3% white, 12.4% African American, 1.7% Asian, 0.3% 
some other race and 1.1% two or more races (Census, 2000).  When reviewing these statistics, 
one should keep in mind that there is a higher incidence of type 1 diabetes in Caucasians than in 
other racial groups (ADA, 2003).  Statistics communicating the number or percentage of African 
American’s with diabetes are sparse; however 5% of reported cases of diabetes in African 
Americans are thought to be T1D (CDC, 2003).  In the EDC there was no exclusion of potential 
participants based on race or gender, and the GBDR did not exclude participants based on race or 
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gender.  All EDC participants for whom banked DNA were available were included in the 
GBDR study. 
Source:  The DNA samples used in this study were extracted from whole blood samples 
from participants of the EDC study.   The data base that was used was also from the PEDC study 
and contained de-identified information from study participants. 
Recruitment:  Participants for the EDC were recruited from the Allegheny County T1D 
Registry and the Children’s Hospital of Pittsburgh Diabetes Registry.  Retention efforts for the 
EDC included mail and telephone contacts.  The GBDR study used banked DNA and an already 
existing data set and did not require resources for retention or recruitment. 
Potential Risks:  There were no risks to the subjects; however, there is the potential for 
great benefit from in that the results may potentially reveal a genetic predisposition to or 
protection from the development of proliferative diabetic retinopathy.  Those involved with the 
study may also receive some professional benefit.  The samples that were provided for the 
GBDR study were de-identified at another facility prior to being released for genotyping.  All 
participants previously consented to having their genetic material investigated by researchers not 
initially directly involved with the EDC provided the samples were de-identified.  All of the data 
generated from this study will be reported as aggregated data and the results of the study will not 
be revealed to the participants in the form of independent personalized genotyping results.  All 
data generated from this study are housed in a database that is secured on a password protected 
computer. 
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7.0  SUMMARY OF STUDY 
The purpose of this study was to investigate the genes involved with angiogenesis and 
vasculogenesis for a potential association with development of PDR.  This project focuses on 
investigating the ADORA2A and the VEGF genes for this association.  The investigation of each 
gene’s association is described individually in detail in the two manuscripts contained within this 
document.  
The study had two specific aims: 
 
Specific Aim 1: Determine if a specific allele, specific genotype or haplotype generated 
for each candidate gene is associated with length of time to diagnosis PDR in individuals with 
T1D. This specific aim is addressed in the two manuscripts contained in this document, “The 
ADORA2A Gene is Associated with Proliferative Diabetic Retinopathy”, and “Vascular 
Endothelial Growth Factor is Associated with Proliferative Diabetic Retinopathy and 
hypertension in Type 1 Diabetes”.  Survival analysis methods were used to investigate this 
specific aim in 2 year increments.  There were no significant associations with regard to time to 
onset of PDR and the genotypes of the SNPs selected for the VEGF gene; however there were 
significant differences between genotypes of the ADORA gene and time to onset of PDR. 
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Specific Aim 2:  Determine if a specific allele, specific genotype and/or haplotype 
generated for each candidate gene is associated with baseline prevalent of PDR.  The planned 
analysis for this specific aim was altered from what had been described in the original proposal 
since most participants had some form of DR.  This specific aim is addressed in the two 
manuscripts contained in this document, “The ADORA2A Gene is Associated with Proliferative 
Diabetic Retinopathy” and “Vascular Endothelial Growth Factor is Associated with Proliferative 
Diabetic Retinopathy and Hypertension in Type 1 Diabetes”.  Additionally to determine if there 
was a suppressor variable effect all genotypes that were not significantly associated with PDR 
were stratified into three groups, an “Early Onset” group identified as those who developed PDR 
after ≤25 years with T1D, a “Late Onset” group defined as those who did not develop PDR   until 
after > 25 years with T1D, and a “Protected” group defined as those who did not develop PDR 
during their follow-up time in the EDC study. 
Analysis of the rs10434 tSNP of the VEGF gene yielded an unanticipated finding.  There 
was marginal association of the GG genotype with baseline prevalent PDR in the univariate 
analysis, but the significance of this association improved substantially in the multivariate 
analysis.  Bivariate analysis of the covariates (included in the multivariate analysis) and the 
genotypes of the rs10434 tSNP found a significant association with baseline prevalent PDR but 
the associated confidence intervals did not inspire confidence in the results.  This finding lead to 
post hoc, investigations of the covariates to determine if there was confounding, or an interaction 
between the variables.  This directed the identification of an association between the GG 
genotype of the rs10434 tSNP of the VEGF gene PDR and the AG genotype of the same tSNP 
and hypertension.   
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Results:   
ADORA2A:  
  The CT genotype of rs2236624 tSNP of the ADORA2A gene was significantly 
associated with prevalence [OR=1.68; (95% CI: =1.11-2.54); p =0.03] and marginally associated 
with incidence [HR=1.34 (95%CI: =0.96-1.87); p=0.09] of PDR in the bivariate analysis.  It was 
also significantly associated with both prevalence [OR=2.19; (95%CI: =1.24-3.86); p=0.038] and 
incidence [HR=1.54; (95%CI: =1.08-2.18); p=0.02] of PDR in the multivariate analysis after 
controlling for covariates.    The TT genotype was associated with both protection from 
development of incident PDR in the bivariate [HR=0.17; (95%CI: =0.04-0.69); p=0.01] and in 
the multivariate [HR=0.01; (95% CI: =0.01-0.72); p=0.02] analysis after controlling for 
covariates.  Analysis of the rs4822489 tSNP found an association between the GT genotype and 
PIPDR in the univariate analysis [HR=1.53; (95%CI: =1.12-2.09); p=0.008], and in the 
multivatiate analyses [HR=1.57; (95%CI: =1.13-2.17); p=0.0067] after controlling for covariates.  
To determine if there was increased risk associated with the 4822489 genotypes and PBPDR 
participants were stratified into late onset (PDR ≥25 years T1d duration), early onset (PDR<25 
years T1D duration), and protected (No PDR during follow-up) groups.  Those with the GT 
genotype were had a significantly increased association [OR=1.93; (95%CI: =1.11-3.35); 
p=0.03] with early onset PDR compared to the protected group.  The association between the GT 
genotype of the rs4822489 tSNP was only marginally significant [OR=1.73; (95%CI: =0.89-
3.36); p=0.12] in the multivatiate analyses after controlling for covariates. 
 
The rs2236634 tSNP found to be associated with both baseline prevalent and incident 
PDR accounts for bases 23,166,024 through 23,168,324 of the ADORA2A gene.  This region of 
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the gene codes for the portion of the g-coupled protein receptor that includes the 4th through the 
7th transmembrane domains which includes several intracellular and extracellular domains as well 
as the entire c-terminus.  Transmembranes 5-7 are highly conserved and are believed to play a 
fundamental role in ligand binding and recognition of agonist/antagonist complexes essential for 
exogenous manipulation of the receptor.  The 22 amino acids bordering the 7th transmembrane 
are essential for protein folding and the cystine residue at position 394 and the argienine at 
position 309 are thought to allow the receptor to bind a multitude of accessory proteins not bound 
by other ARs.  Furthermore this region also plays a part in mitogen activated protein kinase 
(MAPK) stimulation and receptor mobility and is influenced by cholesterol depletion in the cell 
membrane.  Genomic variability in this portion of ADORA2A could result in variability in any of 
the above mentioned functions in this portion of the receptor.  This variability appears to be 
explained by the C and T alleles tagging different haplotypes.  Rs2236624 appears to be in 
linkage disequilibrium with 15 currently known SNPs including a non-synonymous SNP and a 
frame shift polymorphism.   
The region tagged by rs4822489 spans bases 23,148,156-23,158,314.  It includes the 
region of the receptor encompassing transmembranes 1-3.  Transmembrane 3 encompasses aan 
amino acid region associated with ligand binding and may play a role in susceptibility to incident 
PDR, may be used as a target for pharmacogenetics, but requires further exploration. 
Association of ADORA2A with PDR beyond the functions that this portion of the receptor 
performs may be nucleotide variability of the mRNA that could impact its stability and thereby 
receptor density.  The effect of the tagged region of the gene on mRNA stability is currently 
unknown.   Considering the fact, that adenosine is a byproduct of glucose metabolism one must 
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reason that variability in receptor function or availability may affect homeostatic mechanisms and 
biologic mechanisms involving adenosine particularly during periods of hyperglycemia. 
Replicate studies for this gene need to be conducted.  Provided the findings hold this 
information may lead us closer to the development of personalized medicine. Pharmacogenetics 
may be utilized to develope medical therapies for individuals at risk for PDR based on available 
information regarding this portion of the receptor and knowledge of ligands exerting 
agonist/antagonist effects.  Nurses and other health care professionals could initiate earlier 
implementation of preventative therapy and more targeted patient teaching based on the patients 
genetic risk profile. 
VEGF: 
The rs10434 GG genotype was found to be marginally OR=1.23; (95%CI:-0.75-2.26) 
p=0.14 associated with the prevalence of PDR at baseline in the univariate analysis and 
significantly OR=2.40; (95%CI:=1.15-4.99); p=0.0065 associated with baseline prevalent PDR in 
the multivariate analysis.  Interestingly, the rs10434 AG genotype was also associated with 
baseline hypertension as noted above.  The other two tSNPS (rs833069 and rs2146323) and the 
SNP associated with PDR in the DCCT population (rs699947) were not associated with prevalent 
baseline PDR or baseline hypertension in the EDC population.  None of the SNPs were 
associated with incident PDR.  Homozygosity for the rs10434 tSNP is associated with baseline 
prevalent PDR in type 1 diabetes. 
The rs10434 tSNP is the most 3 prime tSNP evaluated and it tags base 43,861,029- 
43,873,511 on the 5 prime to the 3 prime side of the gene respectively.  This section of the gene 
starts in exon 8 and extends through the entire 3’ untranslated region (3’UTR).  Our findings do 
not implicate a specific VEGF isoform in susceptibility to PDR.  The most plentiful isoforms of 
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the protein are the VEGF-121 amino acid isoform (excludes exons 6 and 7); the VEGF-165 
amino acid isoform, (excludes exon 6); theVEGF-189 amino acid isoform, (includes all exons); 
and theVEGF-206 amino acid isoform, (includes all exons plus an additional 6’exon that is only 
found in this isoform).  Our data supports association with the portion of the gene that houses 
exon 8 and given that all isoforms contain exon 8, our data does not support a specific isoform in 
susceptibility to PDR. 
Exons 1-5 of the VEGF gene cover the receptor binding domain while exons 6-7 cover 
the heparin binding domain.  The region implicated by our data excludes exons 1-7 of the gene.   
Investigators have found that portions of exons 7 and 8 working together promote VEGF binding 
to receptors that induce its biologic effects in the heparin binding domain; therefore the heparin 
binding domain cannot be excluded from implication in development of PDR since the region 
tagged by our tSNP excludes a physiologic tag for exon 7 does not exclude endogenous 
biochemical interactions that may require interaction between proteins produced by exon 7 and 8 
acting together or synergistically that cannot be elucidated from physiologic marker tagging 
alone. 
The 3’UTR of VEGF has 9 copies of the consensus AU rich element, which is associated 
with mRNA stability and is regulated by inadequately understood normal physiologic and 
pathologic processes.  Proteins that increase mRNA stability in this region have been identified.  
Other endogenous proteins that have not been identified may bind to and increase mRNA 
stability of VEGF 3’UTR.  Interestingly, binding sites associated with hypoxia have been 
identified and presence of hypoxia does increase VEGF expression.  These characteristics of the 
region of VEGF tagged by the rs10434 tSNP provide a plausible explanation for the results of our 
findings in the GBDR population. 
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This study has implicated both the ADORA2A and the VEGF genes in PDR.  These 
findings further support the heterogeneity involved with genetic susceptibility to PDR amongst 
individuals with T1D and offer increased understanding of the potential mechanisms involved 
with this susceptibility.   
Strengths of this study included the fact that tSNPs were used to investigate the genes of 
interest.  The selection of tSNPs ensured that segments representing the entire gene were 
considered for association with PDR.   The investigation of this relatively homogenous 
population renders the results of this study generalizable to similar Caucasian populations with 
T1D in Western Pennsylvania.  The prospective nature of this study and the wealth of data 
available in the database makes, the EDC an ideal population to investigate the complications of 
diabetes and the covariates associated with the development of these complications.  Additionally 
the prospective nature of the longitudinal information contained in the database facilitates 
investigation of both cross-sectional baseline data and prospective data.   
The strengths of the study are ironically the source of its limitations and areas for future 
investigation.  Tagging SNPs take us to the region and possibly the actual location of the base 
change responsible for the phenotypes under investigation; however it does require that 
evaluation of the underlying variability in these regions be investigated before the actual variant 
responsible for the association is confirmed and since this next step is out of the scope of this 
current project, it is a limitation.  This population was a rather homogenous population of 
Caucasian individuals with T1D; therefore, the results may not be generalized to other 
populations or to those with T2D.   
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Abstract 
Purpose:  The ADORA2A receptor ameliorates many of the deleterious physiologic 
effects associated with tissue injury and biologic stressors, which may include those 
experienced by individuals with diabetes.  We thus, investigated cross-sectionally and 
prospectively the association between the ADORA2A gene and proliferative diabetic 
retinopathy (PDR) in a sample of patients with type 1 diabetes (T1D). 
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Methods:  Study participants were from the Pittsburgh Epidemiology of Diabetes 
Complications (EDC) prospective study of childhood onset (<17 years) T1D, (mean age 
28 years, mean diabetes duration 19 years at enrollment).  Participants underwent 
stereoscopic photography of the retinal fundus at baseline (1986-1988) then biennially, 
for 10 years and again at 18 years.  PDR was defined as grade ≥ 60 in one eye or < 60 
but with panretinal photocoagulation scars consistent with laser therapy, according to 
the modified Airlie House system.  Two haplotype blocks for the ADORA2A gene and two 
tagging single nucleotide polymorphisms (tSNPs) were selected using HAPMAP 
(rs2236624 and rs4822489) 
Results:  Logistic regression analysis of the rs2236624 tSNP revealed an association 
between the CT genotype and prevalent PDR at baseline, both univariately [OR =1.67; 
95%CI = (1.11 – 2.54); p=0.03] and multivariately following covariate adjustment [OR = 
2.17; 95%CI = (1.24 – 3.81); p=0.03].   Univariate Cox proportional hazards regression 
(CPHR) analysis of rs2236624 found significant association between only the TT 
genotype and incident PDR [HR=0.17; 95%CI= (0.042-0.686); p=0.01].  Multivariate 
CPHR analyses found an association between the TT genotype [HR=0.10; 95%CI= 
(0.01-0.72); p=0.02] and the CT genotype [HR=1.54; 95%CI= (1.08-2.18); p=0.01] of 
rs2236624 and incident PDR.  CPHR analysis of the rs4822489 tSNP found an 
association between the GT genotype and incident PDR in the univariate analysis 
[HR=1.53; 95%CI= (1.12-2.09); p=0.01], and in the multivariate analyses after 
controlling for covariates [HR=1.57; 95%CI= (1.13-2.17); p=0.01].      
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Conclusions: Homozygosity for the TT genotype of rs2236624 appears to be protective 
against PDR, while heterozygosity for rs2236624 and rs4822489 seems to increase 
PDR incidence. 
 
 
The ADORA2A Gene is Associated with Proliferative Diabetic Retinopathy  
Introduction: 
Diabetic retinopathy (DR) is the cause of up to 24,000 incident cases of 
blindness in the United States each year, and is the most prevalent cause of blindness 
between the second and seventh decades of life (American Diabetes Association 2008).    
Most individuals with type 1 diabetes eventually experience some form of DR during the 
course of their lives; however, a greater number of  patients with T1D develop 
proliferative diabetic retinopathy (PDR) than do patients with type 2 diabetes, 50% 
verses 10%, respectively (Klein, Klein et al. 1984; Frank 2004).  Historically, it has been  
estimated that as many as 50% of individuals with T1D develop PDR after 15 years, 
and 60% develop PDR by 20 years (Klein, Klein et al. 1984) .  A recent study of T1D 
reported a declining trend (from 38%-26.5%) in PDR development by 20 years of T1D  
duration, while 53%  developed PDR  after having had T1D for  25 years (Pambianco, 
Costacou et al. 2006).  Studies have also shown that presence of DR and/or severity of 
DR attained tends to have characteristics consistent with heritability (Diabetes Control & 
Complications Trial/Epidemiology of Diabetes Interventions and Complications 2000; Rema, 
Saravanan et al. 2002; Hallman, Huber et al. 2005).  The Family Investigation of 
Nephropathy and Diabetes Eye (FIND-Eye) study consisting of European Americans, 
African Americans and Mexican Americans assessed participants for susceptibility to 
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PDR using measures of heritability and found that polygenic heritability for PDR was 
roughly 25%  (Arar, Freedman et al. 2008).  Additionally there are racial differences in 
susceptibility to DR, in individuals from Latin, European and/or African descent 
(Diabetes Control and Complications Trial 1997; Harris, Klein et al. 1998; Tudor, 
Hamman et al. 1998; Trial 2000; Rema, Saravanan et al. 2002; Hallman, Huber et al. 
2005; Arar, Freedman et al. 2008).  
Adenosine is a powerful physiologic mediator thought to modulate cellular 
damage and the resulting tissue injury caused by biologic stressors.  In the presence of 
oxidative stress (OS) hydrogen peroxide is formed in the cytosol rendering vascular 
endothelial cells more permeable (Hecquet, Ahmmed et al. 2008) and adenosine may 
ameliorate this process.  Modulation by adenosine is directed by adenosine receptors 
(ARs), with adenosine A1 receptor having a proinflammatory response to tissue injury 
while the adenosine A2 receptor restricts inflammation and guards tissues from further 
damage (Salmon, Brogle et al. 1993; McKusick 2006).   The rat model has provided 
evidence that ARs have variability in function and  long term  response to ischemic brain 
injury  (Trincavelli, Melani et al. 2008).  Other animal studies have provided evidence 
that ADORA2A protects the kidneys and the heart from ischemic reperfusion injury by 
reducing reactive oxygen species (ROS) generation, limiting mitochondrial damage and 
guarding against apoptosis (Yonehana and Gemba 1999; Xu, Mueller et al. 2005; Xu, 
Park et al. 2005).  An experimental model using bovine retinal endothelial cells has 
provided some evidence that adenosine may play a role in up regulation of expression 
of a gene involved in glucose transport (GLUT1) (Takagi, Kinh et al. 1998).    
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It is postulated that reactive oxygen species (ROS) and oxidative stress (OS) caused by 
long term exposure to hyperglycemia may be responsible for some of the tissue 
damage associated with microvascular complications of diabetes.  OS is also elevated 
in the retina of individuals with diabetes  and may contribute to development of DR 
(Pan, Zhang et al. 2008).  Factors other than OS that are ameliorated by ADORA2A and 
thought to contribute to development of DR are intraocular glycemia and speed of 
glucose metabolism out of the cell,  hypoxia, and inflammation  (Takagi, Kinh et al. 
1998; McKusick 2006).  Additionally, in humans, ADORA2A   in vascular endothelial cells 
plays a part in vasodilation (Iwamoto, Umenmura et al. 1994).    
The role ADORA2A plays in ameliorating effects of biologic stressors in humans 
and animals, coupled with the fact that adenosine’s effects are modulated by ARs 
makes the ADORA2A gene a plausible candidate gene for exploring susceptibility to or 
protection from the development of PDR, although this has not been explored 
previously.  ADORA2A may also affect severity of DR attained.   Thus, we investigated 
both cross-sectionally and prospectively the ADORA2A gene for association with PDR, 
the most severe form of DR, in a sample of patients with T1D. 
Research Design and Methods: 
Population: 
Participants for this study were from the Pittsburgh Epidemiology of Diabetes 
Complications (EDC) prospective study of childhood onset (<17 years) T1D (baseline 
mean age 28 years and mean diabetes duration 19 years).  All participants lived within 
100 miles or a 2.5 hour drive from Pittsburgh at the time of recruitment and were 
members of the Children’s Hospital of Pittsburgh diabetes registry which treated 70% of 
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all T1D patients in Allegheny County.  Potential participants received a letter inviting 
them to have a physical examination and to complete several questionnaires.  There 
were 979 eligible participants, 658 of whom (67.2%) participated in the entire EDC 
evaluation process (Kostraba, Klein et al. 1991; Costacou, Chang et al. 2006).  The 
current study, “Genetic Basis of Diabetic Retinopathy” (GBDR), consists of 496 EDC 
participants for whom DNA was available (75.4%).     
This study was approved by the Institutional Review Board at the University of 
Pittsburgh and written informed consent was obtained from participants prior to baseline 
data collection.  The laboratory data collection methodologies for this population have 
been published previously (Orchard, Dorman et al. 1990; Lloyd, Klein et al. 1995; 
Costacou, Chang et al. 2006).  Briefly, data collection relevant to the GBDR include 
baseline and biennial stereoscopic retinal exams, measurement of blood pressure 
(SBP, DBP), hypertension (HTN), total cholesterol (TCHOL), high density lipoprotein 
(HDL), low density lipoprotein (LDL), triglycerides (TRIG), glycosylated hemoglobin 
(GHb), body mass index (BMI), and documentation of ever smoker status (SMEVR) 
(Lloyd, Klein et al. 1995; Costacou, Chang et al. 2006). 
Determination of Proliferative Diabetic Retinopathy (PDR):   
  Stereoscopic images of the retinal fundus were obtained for participants at 
baseline (1986-1988) then biennially, for those without PDR, over the course of 10 
years and again at 18 years.  Fields 1, 2 and 4 were taken using the Zeiss Camera and 
diagnosis and severity grading were based on assessment of these images by the 
Fundus Photography Reading Center at the University of Wisconsin using the Arlie 
House System.  Three images were used instead of the standard 7 images, since it has 
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been previously validated that this gives acceptable results with good sensitivity and 
reliability.  PDR was defined as either grade ≥ 60 in one eye or grade < 60 but with 
panretinal chorioretinal scars consistent with laser therapy, according to the modified 
Airlie House System.  Baseline PDR was defined as the presence of PDR at the initial 
evaluation.  Incident PDR was defined as PDR first diagnosed at a subsequent biennial 
follow-up time point. 
Genotyping: 
Two major haplotype blocks encompass the ADORA2A gene and two tagging 
single nucleotide polymorphisms (tSNPs) with a minor allele frequency of at least 20%, 
(rs2236624 and rs4822489), were selected to represent these blocks using HAPMAP 
(NCBI build 35) (HapMap Consortium 2003).  The tSNPs were genotyped using 
TaqMan allele discrimination using the ABI Prism® 7000 Sequence Detection System 
with genotype assignment conducted with 2.0 ABI software (Applied Biosystems, Foster 
City, CA).  The assay for each SNP was available through Applied Biosystems.  The 
assay for rs2236624 was a made to order 40X assay while the assay for rs4822489 
was an assay on demand 20X assay.  The genotyping assays were conducted using 
the reagents and concentrations provided in the protocol supplied with the assays.  The 
cycling conditions provided by Applied Biosystems are noted below; however, due to 
poor genotype cluster separation using this protocol, an extended protocol was used 
and generally resulted in improved separation and genotype discrimination. 
TaqMan Conditions- Applied Biosystems Protocol: 
• Step 1: 50ºC for 2 minutes UNG enzyme activation 
• Step 2: 95ºC for 10 minutes AmpliTaq Gold  
• Step 3: 95ºC for 15 seconds to denature DNA 
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• Step 4: 60ºC for 1 minute for annealing  and strand extension 
• Step 5: Repeat 30 times from Step 3  
TaqMan Conditions- Extended Protocol:  
• Step1: 50ºC for 2 minutes UNG enzyme activation 
• Step 2: 95ºC for 10 minutes AmpliTaq Gold  
• Step:3 95ºC for 15 seconds to denature DNA 
• Step 4: 58ºC for 1 minute and 30 seconds for annealing  and strand extension 
• Step 5: Repeat 50 times from step 3  
 
Statistical Analysis 
The data were analyzed using SAS version 9.1.3 (SAS Institute, Inc., Cary,NC).  
The level of significance was established at .05 for two-sided hypothesis testing.  
Initially, Exploratory data analysis were performed to identify data abnormalities that 
may impact the validity of results.  Univariate analysis of categorical predictor variables 
(hypertension, gender, smoking status, genotype) was conducted using contingency 
table analysis with the chi-square test for independence and univariate binary or 
polychotomous logistic regression.  Exact methods were employed if cell sizes were 
small for these testing and modeling procedures.  Continuous predictor variables (age, 
BMI, diabetes duration, GHb, HDL, LDL, TCHOL, TRIG) were analyzed using univariate 
binary or polychotomous logistic regression.  Predictor variables found to be significant 
in the univariate analyses were included as covariates in subsequent multivariate 
analyses. .  Those covariates found to be significant (p<0.05) or marginally significant 
(0.05<p<.10) in the multivariate analysis were included in the initial logistic regression 
model, while only those predictor variables found to be significant (p=<0.05) in the 
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multivariate analysis of the preliminary logistic regression model were used to construct 
the parsimonious model.   
Kaplan-Meier product-limit estimation and the log-rank test were used to 
determine the crude relationship between genotypes and the time to the development of 
PDR in 5 year increments for diabetes duration and in 2.5 year increments using EDC 
follow-up time.  Cox proportional hazards regression methods were used to 
prospectively examine the genotypes of the tSNPs for possible association with incident 
PDR over time.  Cox proportional hazards regression model building strategies included 
forced entry methods to assess genotypes for association with incident PDR.  Stepwise 
Cox proportional hazard regression (significance level of 0.05) methods were used to 
determine which predictor variables, including the tSNPs, were associated with incident 
PDR.  Those predictor variables that had significant (p=<0.05) or had marginal levels of 
significance (0.05 < p < 0.10) were included in the preliminary predictive model.   
Stepwise Cox proportional hazards regression methods were used to prospectively 
analyze those significant and marginally significant predictor variables for association 
with incident PDR and to delineate the most parsimonious predictive model.  For each 
model fitted residual analyses were conducted to identify sources of model 
misspecification and influential observations. 
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Results: 
Demographic and Covariate Evaluations in EDC and GBDR Participants: 
The EDC population at baseline consisted of 98% Caucasians and 51% male 
participants with 32% having prevalent PDR compared to 98% Caucasian, 51% male 
and 29% prevalent cases of PDR in the GBDR participants.    Interestingly, there were 
significant differences between the subset of EDC participants without genetic material 
(n=172) and the GBDR participants on mean GHb, TCHOL, and LDL (Table 1).   
GBDR Participants with Prevalent PDR Verses GBDR Participants with No PDR: 
There were differences between GBDR participants with prevalent PDR and 
those who had not developed PDR at the time of their baseline evaluation (Table 2).  
Those with PDR tended to be older; have a longer duration of T1D; have a higher level 
of GHb; have a higher level of total cholesterol, LDL, and triglycerides; lower level of 
HDL; higher BMI; and greater prevalence of HTN (Table 2).     
 
GBDR Participants with Incident PDR Verses No PDR: 
There was no significant difference between GBDR participants and non-
participants’ mean diabetes duration, gender, HDL, or ever smoker status.  However, 
GHb, HTN, TCHOL, LDL, TRIG, and BMI, differed significantly between GBDR 
participants with incident PDR and those who had not developed PDR during follow-up. 
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Table 1: Baseline Characteristics (mean and Standard Deviation (SD) or Number and 
Percent) GBDR Study Participants’ Compared to EDC Non-Participants 
 
*Significant interaction for group participation and age when age is ≥ 35. 
 
 
 
EDC 
Participants 
with No 
Genetic 
Material 
(n=172) 
 
 
 
 
EDC 
Participants 
in GBDR 
Study 
(n=486) 
 
 
 
 
 
 
 
 
 
 
Variable 
Mean (SD) 
or n (%) 
Mean (SD) 
or n (%) 
 
 
 
 
 
 
 
 
 
Degrees of 
Freedom 
 
 
 
 
 
 
 
 
 
Test 
Statistic 
 
 
 
 
 
 
 
 
 
 
p-value 
Age (years) 28.1 (7.9) 27.4 (7.9)    
Duration 
(years) 
20.1 (7.2) 19.1 (7.6) 1 F=2.23 .1354 
Male 83 (48.3%) 250 (51.4%) 1 Χ2=0.50 .4781 
Glycosylated 
Hemoglobin 
(%) 
10.8 (2.0) 10.3 (1.8) 1 F=13.59 .0002 
Hypertension 33 (19.3%) 73 (15.2%) 1 Χ2=1.07 .3013 
Total 
Cholesterol 
(mg/dl) 
200.9 (45.0) 188.2 (41.0) 1 F=10.56 .0012 
High Density 
Lipoprotein 
(mg/dl) 
53.1 (13.6) 54.1 (11.6) 1 F=0.70 .4015 
Low density 
Lipoprotein 
122.3 (38.1) 114.1 (33.6) 1 F=6.29 .0124 
Triglycerides 133.2 
(123.0) 
101.3 (72.0) 1 F=17.48 <.0001* 
Body Mass 
Index 
23.4 (3.1) 23.6 (3.3) 1 F=0.83 .3621 
Ever Smoker 75 (45.2%) 173 (36.4%) 1 Χ2=3.24 .0719 
Prevalent 
PDR 
62 (36.0%) 142 (29.2%) 1 Χ2=6.55 .0105 
Incident 
PDR 
46 (26.7%) 161 (33.1%) 1 Χ2=1.72 .1900 
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Table 2: Baseline Characteristics (Mean and Standard Deviation (SD) or Number and 
Percent) of GBDR Study Participants by Prevalent PDR Status: 
 
 
 
GBDR 
Prevalent 
PDR (n=142) 
No PDR 
GBDR 
Study 
(n=183) 
 
 
 
 
 
Variable 
 
Mean (±SD) 
Mean 
(±SD) 
 
 
 
 
Degrees of 
Freedom 
 
 
 
 
 
Test Statistic 
 
 
 
 
 
p-value 
Age (years) 37.2 (5.8) 24.8 (8.1)    
Duration 
(years) 
25.1 (6.1) 
P=<0.0001 
16.3 (7.1) 1 F=31.88 <0.0001 
Male 79 (55.6%) 92 
(50.3%) 
1 Χ2=0.56 0.4562 
Glycosylated 
Hemoglobin 
10.3 (1.8) 9.9 (1.7) 1 F=9.73 0.0020 
Hypertension 51 (35.9%) 7 (3.8%) 1 Χ2=25.62 <0.0001 
Total 
Cholesterol 
(mg/dl) 
204.9 (45.3) 173.3 
(32.5) 
1 F=27.49 0.0001 
High Density 
Lipoprotein 
(mg/dl) 
51.7 (11.3) 55.3 
(12.0) 
1 F=7.72 0.0058 
Low Density 
Lipoprotein 
(mg/dl) 
128.9 (38.0) 102.2 
(26.6) 
1 F=26.62 <0.0001 
Triglycerides 120.8 (71.2) 81.1 
(50.1) 
1 F=19.57 <0.0001 
Body Mass 
Index 
24.2 (3.3) 22.9 (3.4) 1 F=7.97 0.0051 
Ever Smoker 66 (47.5%) 61 
(34.7%) 
1 Χ2=<0.01 0.9456 
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Table 3: Baseline characteristics for (mean ± Standard deviation or number and 
percent) of GBDR Study participants by Incident PDR Status: 
 
 
 
GBDR 
Incident 
PDR 
(n=161) 
 
 
 
No PDR 
GBDR Study
(n=183) 
 
 
 
 
 
 
 
Variable 
Mean (SD) 
or n (%) 
Mean (SD) 
or n (%) 
 
 
 
 
 
 
Degrees of 
Freedom 
 
 
 
 
 
 
Test 
Statistic 
 
 
 
 
 
 
 
p-value 
Age (yrs) 25.8 (6.9) 24.8 (8.1)    
Duration 
(yrs) 
17.0 (6.3) 16.3 (7.1) 1 F=0.09 .7675 
Male 79 (49.1%) 92 (50.3%) 1 Χ2=0.0 .9132 
Glycosylated 
Hemoglobin 
(%) 
10.7 (1.9) 9.9 (1.7) 1 F=19.68 <.0001 
Hypertension 15 (9.3%) 7 (3.8%) 1 Χ2=4.08 .0435 
Total 
Cholesterol 
(mg/dl) 
190 (40.0) 173.3 (32.5) 1 F=17.45 <.0001 
High Density 
Lipoprotein 
(mg/dl) 
54.7 (12.1) 55.3 (12.0) 1 F=0.25 .6155 
Low Density 
Lipoprotein 
(mg/dl) 
114.3 (31.4) 102.2 (26.6) 1 F=13.03 .0004 
Triglycerides 106.6 (87.0) 81.1 (50.1) 1 F=10.65 .0012 
Body Mass 
Index 
23.7 (3.0) 22.9 (3.4) 1 F=3.99 .0466 
Ever Smoker 46 (28.8%) 61 (34.7%) 1 Χ2=1.9721 .1602 
 
 
Tagging SNP Analysis for Baseline PDR: 
The allele proportions for the rs2236624 tSNP are 0.21 for T and 0.79 for C.  The 
allele proportions for the rs4822489 tSNP are 0.61for G and 0.39 for T.  Genotype 
counts and percentage with PDR at baseline are shown in Table 4 for both SNPs as 
well as results of contingency table analysis for prevalent PDR at baseline.  The 
rs2236624 tSNP is in Hardy-Weinberg equilibrium (HWE) (Χ2 = 1.47; df =1; p=.50); 
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while the 4822489 tSNP is not in HWE (Χ2 = 5.61; df =1; p=.02).   There is some 
evidence of heterozygote advantage possibly due to the disease enriched sample.                                
 
Table 4:  Prevalent PDR Status by Genotype Distributions of tSNPs  
 Rs2236624 Rs4822489 
Genotypes CC          CT                    TT GG           GT                  TT 
GBDR Participants 308         154                   24 195          212                  84 
%PDR   26           37                   21   26            32                  30 
Total Undetermined 10 (<3%) 5 (<1%) 
Chi-Square     df     p-value* Χ2=6.9076  df=2   p=.0316* Χ2=1.7276   df=2   p=.4216 
*p-values reflect association of tSNP genotypes with prevalent PDR.   
 
The distribution of prevalent PDR differed by genotype for the rs2236624 tSNP 
but not the rs4822489 tSNP.  Using this modeling strategy diabetes duration, 
hypertension, and LDL were identified as predictors of baseline prevalent PDR; 
however, the CT genotype of rs2236624 was also significantly associated with prevalent 
PDR at baseline.  This association was sustained after controlling for the covariates 
listed in Tables 2 and 3.   The most parsimonious model is noted in Table 5.   
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Table 5: Stepwise Multivariate Logistic Regression Model for Baseline PDR (where the 
CC genotype is the tSNP reference)  
 
 
Variable 
Degrees of 
Freedom 
Wald Chi- 
Square 
 
p-value 
Odds Ratio 
(OR) 
95%CI for 
OR 
Duration 1 61.56 <.0001 1.177 1.130-1.226 
High Density 
Lipoprotein 
(mg/dl) 
1 4.77 .0289 0.975 0.954-0.997 
Hypertension 
(Y/N) 
1 16.50 <.0001 3.900 2.022-7.520 
Low Density 
Lipoprotein 
(mg/dl) 
1 9.61 .0019 1.013 1.005-1.021 
Ever Smoker 
(Y/N) 
1 2.38 .1226 1.521 0.893-2.592 
Rs2236624-TT 
vs.CC 
1 0.79 .3732 0.824 0.226-2.998 
Rs2236624-CT 
vs. CC 
1 4.69 .0304 2.171 1.236-3.812 
 
Tagging SNP Analysis for Incident PDR: 
Genotypes of the rs2236624 tSNP were also associated with incident PDR 
(Table 6).  Controlling for covariates associated with development of PDR from the 
univariate analysis and those indicated from the literature, genotypes of the rs2236624 
tSNP remained significant.  BMI and GHb were also significantly associated with the 
incidence of PDR. 
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Table 6: Stepwise Multivariate Cox Regression for Incident PDR tSNP (where the CC 
genotype is the tSNP reference) 
 
 
Variable 
Degrees 
of 
Freedom 
 
Wald Chi 
Square 
 
 
p-Value 
 
Hazard Ratio 
(HR) 
 
95%CI for 
HR 
BMI 1 7.76 0.0053 1.071 1.020-1.124 
GHB 1 18.57 <0.0001 1.213 1.111-1.324 
NLDL 1 5.38 0.0204 1.006 1.001-1.011 
Rs2236624-CT 
vs. CC 
1 5.78 0.0162 1.536 1.082-2.181 
Rs2236624-TT 
vs. CC 
1 5.21 0.0225 0.101 0.014-0.724 
 
Analysis of the rs4822489 tSNP found an association between the GT genotype 
and incident PDR in the univariate analysis [HR=1.53;(95%CI:=1.12-2.09);p=0.008], and 
this finding was sustained in the multivariate analyses [HR=1.57;(95%CI:=1.13-
2.17);p=0.0067] after controlling for covariates (Table 7).   
 
Table 7: Significant Multivariate Variables Associated with Incident PDR tSNP 
Variable Degrees 
of 
Freedom 
 
 
Chi Square 
 
 
p-Value 
 
Hazard ratio 
(HR) 
 
95%CI for 
HR 
Rs4822489-GT 
vs. GG 
1 7.35 .0067 1.568 1.133-2.171
Glycosylated 
Hemoglobin 
1 16.21 <.0001 1.193 1.095-1.300
Low Density 
Lipoprotein 
1 7.59 .0059 1.007 1.002-1.012
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Tagging SNP Analysis for Early Onset PDR, Late Onset PDR and Protected from 
PDR Groupings 
We expanded our analyses of the rs4822489 tSNP in light of our findings to 
determine if it is associated with PDR risk.  GBDR participants were stratified into three 
groups; Early Onset (PDR <25 years T1D duration); Late Onset (PDR ≥ 25 years T1D 
duration); and Protected (no PDR ≥ 25 years T1D duration).  Exploring the association 
between those with early onset versus no PDR during follow-up revealed an association 
between the rs4822489 genotype and prevalence of PDR; however, this relationship 
was diminished in the multivariate analysis (Table 8). 
Table 8:  Rs4822489 (n=254) Early Onset PDR vs. Protection from PDR Development  
Binary Logistic Regression with the GG Genotype as the Reference Group 
 
Variable 
 
Degrees of 
Freedom 
 
Wald Chi 
Square 
 
p-value 
 
Odds Ratio 
(OR) 
 
95%CI for OR
4822489-TT 1 0.40 .5249 1.116 0.543-2.293 
4822489-GT 1 4.72 .0299 1.927 1.107-3.354 
Multivariate Logistic Regression with the GG Genotype Used as the Reference Group 
GHB 1 14.78 .0001 1.458 1.203-1.766 
HTN 1 10.88 .0010 12.915 2.824-59.061 
LDL 1 8.92 .0028 1.018 1.006-1.031 
4822489-TT 1 0.71 .3981 0.926 0.394-2.176 
4822489-GT 1 3.01 .0830 1.716 0.886-3.324 
 
Discussion 
 
Our findings suggest that the region of the ADORA2A gene tagged by the 
rs2236624 SNP is associated with susceptibility to PDR in the GBDR study participants. 
he CT genotype is associated with increased risk of PDR at baseline as well as incident 
PDR, while the TT genotype is associated with decreased risk of incident PDR. 
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The ADORA2A gene spans from base 23,159,092-23,168,324 at chromosome location 
22q11.23.  It is part of the G-protein coupled receptor super family and is expressed in 
the basil ganglia, blood vessels, platelets and other tissues in the body.  It 
encompasses 19 introns and 22 exons at the genomic level while the mature protein 
product is coded for by 1 intron and 2 exons (Hubbard, Aken et al. 2007; Maglott, Ostell 
et al. 2007).   
The rs2236624 tSNP accounts for bases 23,166,024 through 23,168,324 of the 
ADORA2a gene.  This region of the gene begins in an intron and extends through the 
second of the two exons involved in the final protein product.  This region of the gene 
codes for the portion of the receptor that includes the 4th through the 7th transmembrane 
domains which includes several intracellular and extracellular domains as well as the 
entire C terminus.  (Vastrik, D'Eustachio et al. 2007).   
The region of the ADORA2A that appears to be involved in PDR has been 
characterized and the functions it performs may provide plausible mechanisms for the 
associations found in this study.  Transmembrane domains 5-7 are highly conserved 
and are thought to play a vital role in ligand binding and recognition of 
agonist/antagonist complexes crucial for exogenous manipulation of the receptor (Olah 
and Stiles 2000).   Using neuroblastoma cells investigators found that the ADORA2A and 
D2-dopamine receptors located in the cell membrane sometimes act antagonistically 
while at other times they work synergistically enhancing the positive effects of 
adenosine.  ADORA2A  has a 122 amino acid intracellulear terminal C tail that is 3 times 
the length of other GCPRs with the sector bordering the 7th transmembrane  domain 
(22amino acids) being essential to appropriate protein folding while the remaining 100 
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amino acids are not essential for G-protein coupling or ligand binding. ADORA2A houses 
a cystine residue at position 394 and an argienine at position 309 which are thought to 
allow the receptor to bind with a host of accessory proteins not bound by the other ARs 
(Zezula and Freissmuth 2008).  Additionally, this region of the receptor is involved in 
mitogen activated protein kinase (MAPK) stimulation and receptor mobility that is 
influenced by cholesterol depletion in the cell membrane  (Charalambous, Gsandtner et 
al. 2007).   
Variability at the genomic level for this portion of ADORA2A could result in 
variability in any of the above mentioned functions of this portion of the receptor.  This 
variability appears to be explained by the C and T alleles of rs2236624 tagging different 
haplotypes.  Rs2236624 appears to be in linkage disequilibrium with 15 currently known 
SNPs and any underlying variability tagged by rs2236624 could alter receptor function.  
Four of these SNPs are within exons but have synonymous coding, 3 are intronic, 6 lie 
in the 3’untranslated region, one is a non-synonymous SNP and another is a frame shift 
polymorphism.  The association of ADORA2A with PDR beyond the functions that this 
portion of the receptor performs may be due to nucleotide variability of the mRNA 
impacting its stability, and thereby receptor density.  The effect of the tagged region of 
the gene on mRNA stability is currently unknown.  Fully evaluating this segment of the 
gene for underlying variability as well as functional characterization of this variability on 
receptor function or mRNA stability are potential areas of further investigation. 
The region tagged by rs4822489, implicated in incident PDR, spans bases 
23,148,156-23,158,314.  It includes the region of the receptor encompassing 
transmembranes 1-3.  Transmembrane 3 encompasses an amino acid region 
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associated with ligand binding that may play a role in susceptibility to incident PDR.  
This region may be used as a target for pharmacologic intervention, following further 
exploration (Olah and Stiles 2000). 
ADORA2A stimulation has been linked to psychomotor depression, sleep 
induction, immune-suppression, and vasodilation, while its suppression has been linked 
to hypertension, aggression, and inflammation, alleviation of symptoms of ETOH 
withdrawal, and amelioration of neurotoxicity (Yu, Frith et al. 2004).  There is evidence 
that ADORA2A activation decreases the expression of vascular endothelial growth 
factor, a primary mitogen associated with development DR (Olah and Roudabush 
2000).  Experimental models have also shown that the ADORA2A receptor plays a role 
in glucose transport, vasodilation, prevention of apoptosis, hypoxia, inflammation and 
resolution of inflammation (Takagi, Kinh et al. 1998; Lee and Emala 2001; Xu, Mueller 
et al. 2005; Frοbert, Hanink et al. 2006; McKusick 2006).     
This study evaluated the ADORA2A gene however, there are four members of the AR 
family and the potential role of these other three genes in PDR is another area for 
further investigation.  The ADORA1 plays a significant role in the pro-inflammatory 
responses of the cell while ADORA2A, and ADORA2B, play a significant role in limiting 
the cells response to inflammation, thereby producing an anti-inflammatory response.  
While the ADORA3 plays a role in the cell’s response to ischemia (McKusick 2006).   
This study was limited by the fact that the population was largely homogenous 
consisting of 100% T1D patients who were 98% Caucasian.  The fact that the mean 
diabetes duration was 19 years at time of entry into the study limited our ability to 
explore the natural history of DR in reference to the genotype with which one is 
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endowed, since 50% of individuals with T1D develop PDR after 15 years and 60% 
develop PDR after 20 years.  While the participants in our study did have a lower 
incidence of PDR with approximately 27% of the EDC population developing PDR after 
20 years with T1D and 53% developing PDR after 25 years with T1D, this effect is likely 
due to improved glycemic control.   Additionally 85% of the EDC participants had some 
form of DR at the time of entry into the study.   This gave us the opportunity to explore 
the effect of genetic endowment on advancement to development of PDR.  It would be 
beneficial to further explore the ADORA2A gene in another in a population of individuals 
with T2D as well as in another racial/ethnic group. 
This study implicates the ADORA2A gene in PDR in individuals with childhood 
onset T1D.  This association is limited to the portion of the gene characterized above.  
The functions performed by this receptor, its impact on factors known to be important to 
susceptibility to DR, and the implications of the AR family on susceptibility to diabetes 
provide feasible mechanisms for this association.  While replication of these finding is 
paramount to moving forward with this line of investigation, these findings spark interest 
in all of the ARs as playing a role in diabetes complications and suggests that ADORA2A 
may be a therapeutic target to improve protection from complications among individuals 
with diabetes. 
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Abstract 
Purpose:  The VEGF gene, particularly the 5 prime untranslated region has been 
implicated in diabetic retinopathy (DR), a microvascular complication of diabetes 
characterized by erratic vessel formation and visual impairment brought on by hypoxia 
and the damaging byproducts of glucose metabolism in individuals with diabetes.   The 
purpose of this study was to investigate the VEGF gene within the context of proliferative 
diabetic retinopathy (PDR), the most severe form of DR, in a sample of patients with 
type 1 diabetes (T1D). 
Methods:  Participants of this study were drawn from the Pittsburgh Epidemiology of 
Diabetes Complications (EDC) prospective study of childhood onset T1D (mean age 28 
years and mean diabetes duration 19 years at baseline).  Participants had stereoscopic 
images of the retinal fundus at baseline (1986-1988) then biennially for 20 years.  PDR 
was defined as grade ≥ 60 in one eye but < 60 but with panretinal photocoagulation 
scars consistent with laser therapy, according to the modified Arlie House System.  
Three haplotype blocks for the VEGF gene and corresponding tagging single nucleotide 
polymorphisms (tSNPs) were selected using HAPMAP (NCBI Build 36: rs2146326, 
rs833069 and rs10434).  We decided to investigate two additional SNPs based on their 
significance in a similar population (rs3025021 and rs699947). 
Results:  Univariately, rs10434 (GG) was marginally associated with PDR at baseline 
[OR=1.299; 95% CI= (0.747-2.260); p=0.136], but significantly associated with prevalent 
PDR in the multivariate analyses [OR=2.401 95% CI= (1.153-4.99); p=0.007].  Due to 
evidence of possible interaction or confounding; additional analyses were conducted and 
revealed an association between rs10434 (AG genotype) and hypertension at baseline 
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No significant associations were observed for rs10434 with incident PDR.  No significant 
associations were found for rs2146323, rs833069, rs3025021, and rs699947 with 
prevalent or incident PDR. 
Conclusion:  The region of the VEGF gene tagged by the rs10434 SNP is associated 
with susceptibility to PDR and hypertension in this population, a region of the gene not 
previously associated with DR.  
 
Introduction 
Vascular endothelial growth factor (VEGF) has been implicated in the 
pathogenesis of diabetic retinopathy (DR), a microvascular complication of diabetes 
characterized by erratic vessel formation and visual impairment brought on by hypoxia 
and the damaging byproducts of glucose metabolism in individuals with diabetes (Sheetz 
and King 2002; Penn, Madan et al. 2008).  VEGF is a necessary component of normal 
angiogenesis.  It plays a role in wound healing and pathologic processes such as 
retinopathies.   VEGF engineers angiogenesis via initiation of vascular endothelial cell 
proliferation, migration, and tube formation (Favard, Moukadiri et al. 1991; McKusick 
2006; Penn, Madan et al. 2008).  Retinal hypoxia is a component of the pathological 
response to the hyperglycemic state and VEGF is up-regulated in the presence of 
hypoxia (Campochiaro 2000; Perrin, Konopatskaya et al. 2005).  Oxidative stress and 
inflammation are  part of the pathologic response to  hyperglycemia and  these 
processes also result in the up-regulation of VEGF (Penn, Madan et al. 2008), which is a 
primary trigger for the neoangiogenesis and the weak leaky vessels characterized by DR 
  68
(Perrin, Konopatskaya et al. 2005).  Furthermore, VEGF has been well defined in both 
animal and human models as contributing to the development of DR.   
Starting in the early 1990s animal and human studies identified an increase in 
VEGF level in the retina and the vitreous fluid of rats, primates and humans with DR 
(Aiello, Avery et al. 1994; Miller, Adamis et al. 1994; Nakagawa, Chen et al. 2000).  Later, 
genetic association studies reported significant associations between VEGF variants in 
the promoter region of the gene and prevalence of some form of DR or PDR across 
populations with T1D and T2D (Suganthalakshmi, Anand et al. 2006; Uhlmann, Kovacs 
et al. 2006; Nakamura, Iwasaki et al. 2008).  In 2002 investigators reported an 
association between PDR and the 5’-untranslated region, specifically the C-634 allele of 
the VEGF gene, in a population of 268 Japanese patients with T2D [OR=7.7; 95%CI= 
(1.8-30.9); p=.002] (Awata, Inoue et al. 2002). Subsequently, investigators in England 
reported an association between the VEGF-460C allele and development of PDR in a 
Caucasian population of individuals with T1D and T2D [OR 2.5; 95%CI= (1.20-5.23); 
p0.027]  (Ray, Mishra et al. 2004).  In a population of 210 T2D patients of east Indian 
ancestry investigators found that the C-7T, the T-1498C, and the C-634G, 
polymorphisms of the VEGF gene were significantly associated with DR [OR=4.37; 
95%CI= (2.44-7.84); p0.0001] (Suganthalakshmi, Anand et al. 2006).  Interestingly, 
Nakamura and colleagues found a significant association between SNP-2578C/A of the 
VEGF gene and PDR with the AA genotype at SNP-2578 being strongly associated with 
PDR and with DR after controlling for diabetes duration.   They found no association for  
the C-634G polymorphism of the VEGF gene and prevalence of DR  (Nakamura, 
Iwasaki et al. 2008).  Investigators of the Diabetes Control and Complications Trial 
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(DCCT) provided evidence that three SNPs (rs3025007, rs3025020 and rs3025035) of 
the VEGF gene were associated with severe retinopathy in a univariate model, while 
eight SNPs (rs699947, rs833070, rs2146323, rs3035007, rs3025010, rs3025020, 
rs3025021, and rs3025028) were associated with severe retinopathy in the multivariate 
analyses, (Al-Kateb, Mirea et al. 2007) potentially indicating a suppressor effect for 
SNPs not identified in the univariate analyses.  Finally, there is evidence that two SNPs 
in the promoter region of VEGF, rs13207351, specifically the  CC and the AA genotype,  
and rs1570360, specifically the AA genotype, were significantly associated with PDR in 
a mixed population of T1D and T2D patients (Churchill, Carter et al. 2008). 
We decided to investigate the entire VEGF gene and its flanking regions using 
tSNPs and did so in a longitudinal cohort where incident PDR could be evaluated.    
 
Research Design and Methodology: 
Population:  
This study consists of participants of the Pittsburgh Epidemiology of Diabetes 
Complications (EDC) prospective study of childhood onset (<17 years of age) T1D.  
Mean age and diabetes duration at time of entry into the study were 28 years and 19 
years, respectively.  Inclusion criteria for the study required that participants 1) were 
members of the Children’s Hospital of Pittsburgh Diabetes Registry or Allegheny County 
Type 1 Diabetes Registry and 2) live within 100 miles or within a two and a half hour 
drive from Pittsburgh.    Nine hundred seventy-nine eligible registrants were sent a letter 
inviting them to have a physical exam and to fill out several questionnaires.  Six hundred 
fifty-eight (67.2%) took part in the full EDC evaluation process.  Participants of the 
  70
current study, “The Genetic Basis of Diabetic Retinopathy” (GBDR), are made up of 496 
(75.4%) individuals for whom genetic material was available. A more thorough 
description of the methods have been previously published (Kostraba, Klein et al. 1991; 
Costacou, Chang et al. 2006). 
The Institutional Review Board at the University of Pittsburgh approved this study 
and written informed consent was acquired from participants preceding baseline data 
collection.  Procedures for laboratory data collection for participants of this study have 
been described in prior publications (Orchard, Dorman et al. 1990; Lloyd, Klein et al. 
1995; Costacou, Chang et al. 2006).  In short, data collection consists of baseline and 
biennial stereoscopic retinal fundus exams, measurement of blood pressure (SBP, 
DBP), documentation of hypertension (HTN) defined as SBP ≥ 140 and/or DBP ≥ 90, 
total cholesterol (TCHOL), high density lipoprotein (HDL), low density lipoprotein (LDL), 
triglycerides (TRIG), glycosylated hemoglobin (HGB), body mass index (BMI), and 
documentation of smoking status (Lloyd, Klein et al. 1995; Costacou, Chang et al. 2006).  
Potential covariates were selected based on variables reported in the literature to be 
associated with PDR and included variables found to be significant based on findings of 
the univariate analysis. 
Genotyping: 
Three tSNPs with a minor allele frequency of at least 20% and representing the 
three main haplotype blocks of VEGF were selected via HAPMAP (NCBI build 36; 
rs833069, rs2146323 and rs10434).  After reviewing the findings of the DCCT, which 
consisted primarily of a population of Caucasian individuals with T1D very similar to the 
demographics of our cohort, we decided to explore two additional SNPs (rs699947 and 
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rs3025021) associated with PDR in the DCCT; however the rs3025021 assay failed to 
provide genotype data and was excluded from analyses.  Removal of this SNP did not 
impact our evaluation of the entire VEGF gene given that we were already investigating 
tSNPs and all of those assays worked well.   
The tSNPs were genotyped using TaqMan allele discrimination using the ABI 
Prism® 7000 Sequence Detection System with genotype assignment conducted with 
2.0 ABI software (Applied Biosystems, Foster City, CA).  The assay for each SNP was 
available through Applied Biosystems (All assays were made to order 40X assays).  
The genotyping assays were conducted using the reagents and concentrations provided 
in the protocol supplied with the assays.  The cycling conditions provided by Applied 
Biosystems are noted below and were used for rs699947, rs2146323 and rs8333069; 
however due to poor genotype cluster separation using this protocol, an extended 
protocol was used for rs10434 and resulted in improved separation and genotype 
discrimination. 
TaqMan Conditions- Applied Biosystems Protocol: 
• Step 1: 50ºC for 2 minutes UNG enzyme activation 
• Step 2: 95ºC for 10 minutes AmpliTaq Gold  
• Step 3: 95ºC for 15 seconds to denature DNA 
• Step 4: 60ºC for 1 minute for annealing  and strand extension 
 
• Step 5: Repeat 30 times from Step 3  
 
TaqMan Conditions- Extended Protocol:  
• Step1: 50ºC for 2 minutes UNG enzyme activation 
• Step 2: 95ºC for 10 minutes AmpliTaq Gold  
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• Step:3 95ºC for 15 seconds to denature DNA 
• Step 4: 58ºC for 1 minute and 30 seconds for annealing  and strand extension 
 
• Step 5: Repeat 50 times from step 3  
 
PDR Defined: 
Stereoscopic images of the retinal fundus were obtained for participants at 
baseline (1986-1988) then biennially, for those without PDR, over the course of 10 
years and again at 18 years.  Fields 1, 2 and 4 were taken using the Zeiss Camera and 
diagnosis and severity grading were based on assessment of these images by the 
Fundus Photography Reading Center, at the University of Wisconsin using the Arlie 
House System.  Three images were used instead of the standard 7 images, since it has 
been previously validated that this gives acceptable results with good sensitivity and 
reliability.  PDR was defined as either grade ≥ 60 in one eye or grade < 60 but with 
panretinal chorioretinal scars consistent with laser therapy, according to the modified 
Airlie House System.  Baseline PDR is defined as the presence of PDR at the initial 
evaluation.  Incident PDR was defined as PDR diagnosed at a subsequent biennial 
follow-up time point. 
Analyses: 
Hardy-Weinberg equilibrium was evaluated for each SNP separately.  Data were 
analyzed using SAS version 9.1.3 (SAS Institute, Ins., Cary, NC).  P-values less than 
0.05 were considered statistically significant.  Analysis of univariate categorical 
variables (hypertension, gender, smoking status and genotype) were conducted using 
logistic regression, chi-square goodness of fit or exact chi square if cell sizes were 
small.  Continuous variables age, body mass index (BMI), diabetes duration, 
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glycosylated hemoglobin (GHb), high density lipoprotein (HDL), low density lipoprotein 
(LDL), triglycerides (TRIG) were analyzed using univariate, binary or polychotomous 
logistic regression.  Multivariate analyses were conducted using binary and multivariate 
logistic regression.  Variables that achieved levels of significance or near significance 
(<0.20) in the univariate analysis were included in the multivariate analysis as 
covariates.  Variables previously reported in the literature as being associated with PDR 
were also included as covariates in the analysis.   
Association between the SNPs and prevalence of PDR at baseline were 
determined using bivariate logistic regression.  Association between the SNPs and 
prevalence of PDR at baseline controlling for covariates was determined using 
multivariate logistic regression methods.  Cox proportional hazards regression methods 
were used to prospectively assess incident PDR in relation to the participants’ SNP type.  
Model building strategies consisted of forced entry and or backward regression 
strategies using covariates found to be significant or near significant in the univariate 
analysis.  Predictor variables found to be significant or near significant in the univariate 
analysis were included in the preliminary model.  Predictor variables found to be 
significant or marginally significant in the preliminary model were included in the final 
model or the most parsimonious model.  Backward regression models were used to 
analyze SNPs bivariately for association with PDR.  Forward multivariate Cox 
proportional hazards regression methods were used to prospectively analyze tSNPs for 
an association with PDR controlling for covariates. 
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Post Hoc Analyses 
Given the increased association between the GG genotype of rs10434 in the 
multivariate analyses we decided to conduct additional analyses using logistic 
regression to further explore these findings.   Additionally chi square goodness of fit test 
was used to assess categorical predictor variables for association with rs10434; while, 
general linear modeling was used to assess the continuous dependent variables for 
association with rs10434 genotypes. 
 
Results: 
Demographic and Covariate Evaluations in EDC and GBDR Participants: 
 
The EDC population consists of 98% Caucasians, is 49% female, with 32% 
having prevalent PDR, while the GBDR participants consists of 98% Caucasians, and 
49% female, with 29% having prevalent PDR.   Interestingly, there were significant 
differences between the subset of EDC participants without genetic material (n=172) and 
the GBDR participants on mean GHb, TCHOL, and LDL (Table 1).  Within the GBDR 
population there were differences in baseline characteristics between those with 
prevalent PDR and those who had not developed PDR at the time of baseline evaluation 
(see Tables 2 and 3).  Those with PDR tended to be older; have a longer duration of 
T1D; have a higher level of GHb; have higher levels of total cholesterol, LDL, and 
triglycerides;   lower level of HDL; higher BMI; and greater prevalence of HTN (Table 2 
and 3).     
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Table 1: Baseline Characteristics (Mean and Standard Deviation (SD) or Number and 
Percent) GBDR Study Participants’ Compared to EDC Non-Participants 
 
EDC 
Participants 
with No 
Genetic 
Material 
(n=172) 
EDC 
Participants 
in GBDR 
Study 
(n=486) 
 
 
 
 
 
 
 
Variable 
Mean (SD 
or n (%) 
Mean (SD 
or n (%) 
 
 
 
 
 
Degrees 
of 
Freedom 
 
 
 
 
 
 
 
F-value 
 
 
 
 
 
Wald 
Chi 
Square 
 
 
 
 
 
 
 
p-value 
Age (years) 28.1 (7.9) 27.4 (7.9)     
Duration 
(years) 
20.1 (7.2) 19.1 (7.6) 1 2.23  .1354 
Male 83 (48.3%) 250 
(51.4%) 
1 NA 0.50 .4781 
Glycosylated 
Hemoglobin 
(%) 
10.8 (2.0) 10.3 (1.8) 1 13.59 NA .0002 
Hypertension 33 (19.3%) 73 (15.2%) 1 NA 1.07 .3013 
Total 
Cholesterol 
(mg/dl) 
200.9 
(45.0) 
188.2 
(41.0) 
1 10.56 NA .0012 
High Density 
Lipoprotein 
(mg/dl) 
53.1 (13.6) 54.1 (11.6) 1 0.70 NA .4015 
Low density 
Lipoprotein 
122.3 
(38.1) 
114.1 
(33.6) 
1 6.29 NA .0124 
Triglycerides 133.2 
(123.0) 
101.3 
(72.0) 
1 17.48 NA <.0001* 
Body Mass 
Index 
23.4 (3.1) 23.6 (3.3) 1 0.83 NA .3621 
Ever Smoker 75 (45.2%) 173 
(36.4%) 
1 NA 3.24 .0719 
Prevalent 
PDR 
62 
(36.04%) 
142 
(29.22%) 
1 NA 6.55 .0105 
PDR 46 
(26.74%) 
161 
(33.13%) 
1 NA 1.72 .1900 
*Significant interaction for group participation and age when age is ≥ 35. 
p-values reflect between group comparisons 
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Table 2: Baseline Characteristics (Mean and Standard Deviation (SD) or Number and 
Percent) of GBDR Study Participants by Prevalent PDR Status 
 
 
GBDR 
Prevalent 
PDR 
(n=142) 
No PDR 
GBDR 
Study 
(n=183) 
 
 
 
 
 
Variable 
Mean 
(SD) 
Mean 
(SD) 
 
 
 
Degrees 
of 
Freedom 
 
 
 
 
 
F-Value 
 
 
 
 
Wald Chi- 
Square 
 
 
 
 
 
p-value 
Age (years) 37.2 (5.8) 24.8 (8.1) 1    
Duration 
(years) 
25.1 (6.1) 16.3 (7.1) 1 31.88 NA <.0001 
Male 79 
(55.6%) 
92 
(50.3%) 
1 NA 0.56 .4562 
Glycosylated 
Hemoglobin 
(%) 
10.3 (1.8) 9.9 (1.7) 1 9.73 NA .0020 
Hypertension 51 
(35.9%) 
7 (3.8%) 1 NA 25.62 <.0001 
Total 
Cholesterol 
(mg/dl) 
204.9 
(45.3) 
173.3 
(32.5) 
1 27.49 NA .0001 
High Density 
Lipoprotein 
(mg/dl) 
51.7 
(11.3) 
55.3 
(12.0) 
1 7.72 NA .0058 
Low Density 
Lipoprotein 
(mg/dl) 
128.9 
(38.0) 
102.2 
(26.6) 
1 26.62 NA <.0001 
Triglycerides 120.8 
(71.2) 
81.1 
(50.1) 
1 19.57 NA <.0001 
Body Mass 
Index 
24.2 (3.3) 22.9 (3.4) 1 7.97 NA .0051 
Ever Smoker 66 
(47.5%) 
61 
(34.7%) 
1 NA <.01 .9456 
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Table 3: Baseline characteristics for (mean ± Standard deviation or Number and 
Percent) of GBDR Study participants by Incident PDR Status 
 
GBDR 
Incident 
PDR 
(n=161) 
No PDR 
GBDR 
Study 
(n=183) 
 
 
 
 
 
Variable 
Mean 
(±SD) 
Mean 
(±SD) 
 
 
 
Degrees 
of 
Freedom 
 
 
 
 
 
F-Value 
 
 
 
 
Wald 
Chi- 
Square 
 
 
 
 
 
p-value 
Age (years) 25.8 (6.9) 24.8 (8.1)     
Duration 
(years) 
17.0 (6.3) 16.3 (7.1) 1 0.09 NA .7675 
Male 79 
(49.1%) 
92 
(50.3%) 
1 NA 0.01 .9132 
Glycosylated 
Hemoglobin 
10.7 (1.9) 9.9 (1.7) 1 19.68 NA <.0001 
Hypertension 15 
(9.3%) 
7 (3.8%) 1 4.08 NA .0435 
Total 
Cholesterol 
(mg/dl) 
190 
(40.0) 
173.3 
(32.5) 
1 17.45 NA <.0001 
High Density 
Lipoprotein 
(mg/dl) 
54.7 
(12.1) 
55.3 
(12.0) 
1 0.25 NA .6155 
Low Density 
Lipoprotein 
(mg/dl) 
114.3 
(31.4) 
102.2 
(26.6) 
1 13.03 NA .0004 
Triglycerides 106.6 
(87.0) 
81.1 
(50.1) 
1 10.65 NA .0012 
Body Mass 
Index 
23.7 (3.0) 22.9 (3.4) 1 3.99 NA .0466 
Ever Smoker 46 
(28.8%) 
61 (34.7) 1 1.97 NA .1602 
 
 
 SNP Analysis: 
All four of the VEGF polymorphisms investigated were in HWE.  Only rs10434 
resulted in significant findings.  No associations were found between prevalent PDR and 
rs833069 (p=.4732), rs699947 (p=.8576), and rs2146323 (p=.6701) (see Table 9).  
Additionally, no association was found between incident PDR and rs833069 (p=.8540), 
rs699947 (p=.8801) and rs2146323 (p=.5904) (see Table 9).  This lack of association 
was maintained after controlling for covariates.  All subsequent analyses were 
conducted only with rs10434.   
Binary logistic analysis revealed a marginal association between rs10434 and 
PDR [OR=1.3, 95% CI = (0.75-2.3) and OR=0.87 95%CI= (0.52-1.5)] for the GG and the 
AG genotypes, respectively.  Controlling for covariates using the full covariate model 
revealed a significant association between diabetes duration (p = <.0001), HDL (p = 
.04), HTN (<.0001), LDL (p=.005) and the homozygous (GG) genotype ((p=.0005).   The 
most parsimonious model which included the above noted variables revealed significant 
associations between prevalent PDR and duration, HDL, LDL, HTN, rs10434 (GG) 
genotype (see Table 4). 
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 Table 4: Variables Associated with Baseline Prevalent PDR  
 
Variable 
Degrees of 
Freedom 
Wald Chi- 
Square 
 
p-value 
Odds Ratio 
(OR) 
95%CI for 
OR 
rs10434-GG 
vs. AA 
1 7.40 .0065 2.401 1.154-4.999 
Rs10434-AG 
vs. AA 
1 1.10 .2932 1.172 0.595-2.309 
DUR 1 66.88 <.0001 1.177 1.132-1.224 
HTN 1 15.29 <.0001 3.675 1.914-7.075 
HDL 1 6.88 .0087 0.971 0.949-0.993 
LDL 1 11.04 .0009 1.013 1.005-1.021 
 
Bivariate Cox regression analysis of the genotypes of rs10434 for association 
with PDR found that there was no association between the AG genotype [HR=0.928; 
95%CI= (0.625-1.379); p=0.7110)] and the GG genotype [HR=0.907; 95%CI= (0.560-
1.418); p=.6683], using the AA genotype as the reference. 
Post Hoc Analysis of rs10434: 
    The association between PDR and the GG genotype of rs10434 controlling 
independently for duration, HTN, LDL, and HDL was evaluated.  In the analysis of 
duration and LDL the p-value for the GG genotype remained significant; however the 
95% CI was suboptimal; while in the analysis of HTN and LDL, the genotype achieved 
marginal significance (see Tables 5-8).  We therefore decided to explore the covariates 
for an association with the rs10434 genotype.    
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 Table 5:  Analysis of rs10434 Genotype Controlling for Diabetes Duration with Prevalent 
PDR at baseline: 
 
 
Variable 
 
Degrees of 
Freedom 
Wald Chi- 
Square  
Value 
  
 
p-value 
 
Odds Ratio 
(OR) 
 
95% CI for 
OR 
Rs10434-GG 1 4.58 .0323 1.735 0.909-3.313 
Rs10434-AG 1 1.50 .2203 0.983 0.539-1.791 
Diabetes 
Duration 
1 97.43 <.0001 1.193 1.152-1.236 
 
Table 6:  Analysis of rs10434 Genotype Controlling for Hypertension with Prevalent PDR 
at Baseline 
 
 
Variable 
 
Degrees of 
Freedom 
Wald chi- 
Square 
Value 
 
 
 p-value 
 
Odds Ratio 
(OR) 
 
95% CI for 
OR 
Rs10434-GG 1 3.46 .0627 1.672 0.907-3.085 
Rs10434-AG 1 0.32 .5729 1.142 0.643-2.026 
Hypertension 1 54.63 <.0001 8.161 4.677-14.241
 
Table 7: Analysis of rs10434 Genotype Controlling for LDL with PDR 
Variable Degrees of 
Freedom 
Wald Chi 
Square 
 
p-value 
Odds Ratio 
(OR) 
95% CI for 
OR 
Rs10434-GG 1 3.90 .0484 1.545 0.850-2.807 
Rs10434-AG 1 1.73 .1883 0.929 0.530-1.628 
LDL 1 31.74 <.0001 1.020 1.013-1.027 
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Table 8:  Analysis of rs10434 Genotype Controlling for HDL with PDR 
 
Variable 
Degrees of 
Freedom 
Wald Chi- 
Square 
 
p-value 
Odds Ratio 
(OR) 
95%CI for 
OR 
Rs10434-GG 1 2.76 0.0968 1.366 0.777-2.402 
Rs10434-AG 1 1.82 0.1769 0.883 0.520-1.498 
HDL 1 9.86 0.0017 0.971 0.954-0.989 
 
Logistic regression was used to assess the relationship between the rs10434 
tSNP and the categorical variable hypertension.  There was no significant association 
between the rs10434 genotype and diabetes duration, LDL, or HDL.  Interestingly, this 
analysis revealed a significant association between rs10434 and hypertension with the 
AG genotype showing a direct association with hypertension while the GG genotype did 
not (see Table 9). 
  
Table 9: Summary VEGF Genotype Frequencies and Associations with Baseline PDR, Hypertension and Incident PDR 
SNP/Genotype Frequency Baseline PDR Count 
(%)  ChiSq 
Incident PDR Count 
(%)  ChiSq 
Hypertension Count 
(%) ChiSq 
Rs10434     
AA 102 29 (28) 36 (35) 23 (23) 
AG 241 62 (26) 82 (34) 29 (12) 
GG 141 48 (34) 43 (31) 21 (15) 
Chi Square  .22 .89 .05 
Rs833069     
CC 66 15 (23) 23 (35) 8 (12) 
CT 212 64 (30) 71 (33) 31 (15) 
TT 212 64 (30) 66 (31) 33 (16) 
Chi-Square p-value  .47 .85 .81 
Rs699947     
AA 101 31 (31) 31 (31) 16 (16) 
AC 233 65 (28) 78 (33) 36 (15) 
CC 148 44 (30) 50 (34) 19 (13) 
Chi-Square p-value  .86 .88 .73 
Rs2146323     
AA 52 17 (33) 14 (27) 7 (14) 
AC 210 62 (30) 67 (32) 34 (16) 
CC 227 64 (39) 80 (35) 32 (14) 
Chi-Square p-value  .81 .59 .81 
 
 
 
83 
 
 Discussion: 
The outcomes of our study suggest that the region of the VEGF gene tagged by 
the rs10434 SNP is associated with susceptibility to PDR and hypertension in the GBDR 
study participants.  The GG genotype is marginally associated with increased PDR at 
baseline in the univariate analysis but significantly associated with PDR in the 
multivariate analysis, while the AG genotype is significantly associated with 
hypertension at baseline in the univariate analysis.  The rs10434 tSNP is the most 3 
prime tSNP evaluated and LD appears to deteriorate around nucleotide 43,861,029 on 
the 5 prime side and around 43,873,511 on the 3 prime side (HapMap 2006).  This 
section of the gene originates in exon 8 and encompasses the 3 prime untranslated 
region (3’UTR) (Onesto, Berra et al. 2004; HapMap 2006). 
Our results do not implicate a specific VEGF isoform in susceptibility to PDR.  
The most plentiful isoforms of the protein are the VEGF-121 amino acid isoform 
(excludes exons 6 and 7); the VEGF-165 amino acid isoform, (excludes exon 6); 
theVEGF-189 amino acid isoform, (includes all exons); and theVEGF-206 amino acid 
isoform, (includes all exons plus an additional 6’exon that is only found in this isoform).  
Our data supports association with the portion of the gene that houses exon 8 and given 
that all isoforms contain exon 8, our data does not support a specific isoform in 
susceptibility to PDR.  Exon 8 has been associated with vascular morphogenesis 
(Ruhrberg, Gerhardt et al. 2002) and attenuation of spontaneous hypertension in rats 
(Vilar, Waeckel et al. 2008).  This is interesting given our data that supports an 
independent association of rs10434 with hypertension.   
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VEGF receptor binding is not likely to be involved in susceptibility to PDR but 
heparin binding may play a role.  Exons 1-5 of the gene cover the receptor binding 
domain while exons 6-7 cover the heparin binding domain (Penn, Madan et al. 2008), 
both domains are not associated with PDR in our population.  The region implicated by 
our data excludes exons 1-7 of the gene, however heparin binding cannot be ruled out 
as a mechanism for our association given that investigators have found that portions of 
exons 7 and 8 working together promote VEGF binding to receptors that induce its 
biologic effects in the heparin binding domain (Jia, Bagherzadeh et al. 2006; von 
Wronski, Raju et al. 2006).   
VEGF transcript stability may play a role in susceptibility to PDR.  The 3’UTR is 
primarily responsible for VEGF mRNA stability and regulation and the entire 3’UTR is 
implicated by our data.  This region has 9 copies of the consensus AU rich element, 
which is associated with mRNA stability and is controlled by inadequately understood 
normal physiologic and pathologic processes.  Three proteins that increase stability of 
mRNA in this region, have been identified; protein-interacting protein 2, HuR of the 
ELAV family, and hnRNPL, a ribonucleoprotein.  Other endogenous proteins may bind 
to and increase the stability of VEGF 3’UTR mRNA; however they have not yet been 
identified.  Interestingly, binding sites associated with hypoxia have been identified 
(Onesto, Berra et al. 2004) and the presence of hypoxia does increase VEGF 
expression (Penn, Madan et al. 2008).  These characteristics of the region of the VEGF 
gene tagged by the rs10434 SNP provide a plausible explanation for the results of our 
findings in the GBDR population. 
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 Several previous studies have implicated the 5’region of VEGF with PDR; 
however our data does not support a role for the 5 prime region of the gene.  Churchill 
and colleagues conducted a case-control study of 45 individuals with type 1 or 2 
diabetes and 61 controls with T1D or T2D but no PDR for genetic association with 
VEGF.   These investigators analyzed SNPs located in the 5’untranslated region and 
intronic SNPs encompassing the VEGF gene.  They found the rs2146323 tSNP to be 
associated with PDR (Churchill, Carter et al. 2008).   Possible reasons for the 
differences in our studies may be the respective population sizes.  Additionally their 
population consisted of both T1D and T2D patients who tend to have different rates of 
PDR development.  The diabetes duration of the cases ranged from 7-44 years while 
controls diabetes duration ranged from 14-50 years and covariates such as 
hypertension were not considered.  Interestingly our results are similar to those of 
Finnish investigators who found no association between rs2146223 and PDR (Liinamaa 
2007).   
  In a study of 349 Caucasians with T2D, investigators found that while VEGF 
levels were elevated in the vitreous fluid and blood of individuals with PDR there was no 
genetic association with rs2010963 (located in the 5’untranslated region of the VEGF 
gene) and PDR.  They controlled for hypertension (cross-sectional) but did not find an 
association between PDR and hypertension (Petrovic, Korosec et al. 2008).  
Investigators of the Diabetes Control and Complications trial (DCCT) did not find an 
association between the rs699947 SNP and PDR in their univariate analysis. 
Interestingly they did find an association between the SNP and PDR in their multivariate 
analysis. These findings suggest that there may be a yet unidentified covariate effect 
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 related to the rs699947 SNP’s genotypes and PDR, similar to the relationship we found 
between the rs10434 tSNP, hypertension and PDR.  Awata et al investigated 268 
Japanese patients with T2D for an association between DR and the 5’untranslated 
region of the VEGF gene.  They did find an association between non proliferative DR 
and the 5’untranslated region of VEGF, however they did not control for hypertension or 
diabetes duration (Awata, Inoue et al. 2002).  Their findings were supported by a study 
of Caucasians patients with T1D and T2D; however this study was limited by the fact 
that there were no controls without DR (Ray, Mishra et al. 2004). 
 
The elevated levels of VEGF, erratic vessel formation and genetic association 
studies linking VEGF to DR has lead to the use of VEGF suppressors, such as 
Pegaptanib and Ranibizumab, as a therapeutic intervention for the treatment of 
retinopathies.  There has been some success associated with these therapies; however 
given VEGF’s heterogeneity and pleiotropic effects the suppression of VEGF is also 
associated with hypertension, impaired wound healing, proteinuria disrupted capillary 
vessel formation, disrupted bone growth, infertility and impaired muscle restoration and 
cardio-adaptive processes (Simo and Hernandez 2008).  Low dose statins such as 
Simvastatin have been found to increase reparative VEGF production leading to normal 
oxygen levels in the retina and inhibition of pathologic vessel growth.  Interestingly, 
higher doses resulted in pathologic neovascularization, retinal ischemia and endothelial 
cell apoptosis (Reinhold, O'Neill et al. 2008).  While there are side effects to these 
drugs, the success that has been noted in treatment of retinopathy also supports that 
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 level of VEGF, controlled via transcript stability, is a viable hypothesis to support the 
association of the 3’UTR of the VEGF gene in susceptibility to PDR. 
 
This study has provided additional information regarding VEGF and the development of 
PDR.  Unlike other studies it has implicated the 3’UTR of the VEGF gene.  This study is 
strengthened by the fact that it used tSNPs that are representative of the entire VEGF 
gene to investigate the association of VEGF with PDR.   While the DCCT investigators 
did investigate the 5’UTR and intronic SNPs spanning the entire VEGF gene they did 
not use tSNPs and may not have fully covered the 3’UTR tagged by rs10434.    
 
All of these studies are building our knowledge of the role of VEGF in the 
development of DR and is adding to our knowledge of its pleiotropic effects and may 
help in the development of more specific gene based therapeutic interventions.  These 
studies are also moving us closer to being able to provide patients with customized 
preventative care and tailored therapeutic interventions through a better understanding 
of the mechanisms involved with susceptibility to DR, particularly PDR. 
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